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Abstract 
 
Objectives: 1) To improve an existing COPD model by incorporating the distinction 
between mild, moderate, severe and very severe COPD and by quantifying the 
progression of COPD over these stages 2) To use the improved model to estimate the 
potential impact of smoking cessation programs offered to COPD patients and project 
their effect on the future burden of COPD. 
 
Methods: An existing population model for COPD, which is a module of the RIVM 
Chronic Disease model, was extended with disease progression over time. Prevalent 
cases in the starting year were distributed over 4 severity stages mild (28%), moderate 
(54%), severe (15%) and very severe (3%) (GOLD-classification). The severity 
distribution was based on data from GP registrations. The COPD incidence was 41% in 
mild, 55% in moderate and 4% in severe. Disease progression was modelled as annual 
decline in lung function in FEV1% predicted. The Lung Health Study was used to 
estimate gender, age, smoking and baseline FEV1% predicted dependent values of lung 
function decline and one-time increase in lung function associated with smoking 
cessation. A meta-analysis was done to obtain severity stage specific mortality rates. 
The new model was used to project COPD prevalence, mortality and costs by COPD 
severity stage over the period 2000-2025 (the base-case scenario). A series of 
sensitivity analyses was performed to assess the robustness of the results to changes in 
input data and assumptions. 
The new model was used to compare two scenarios on increased implementation of two 
smoking cessation interventions, minimal counselling by the general practioner (H-MIS) 
and intensive counselling with bupropion (IC+Bupr). They were compared to the base-
case scenario in terms of life-years, QALYs, interventions costs and savings of COPD-
related costs. In the scenarios H-MIS or IC+Bupr was implemented for a period of either 
1 year, 10 years or 25 years and reached 25% of the smokers. Smoking cessation 
results in a one-time increase in lung function and a lower annual decline in FEV1% 
predicted, which results in less disease progression and less mortality among COPD 
patients who quit smoking. Future costs and effects of these scenarios were discounted 
at 4%. Incremental cost-effectiveness ratios were calculated as (additional intervention 
costs minus the savings in COPD-related health care costs)/ gain in health outcomes. 
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Results: In the base-case scenario, the total number of COPD patients increases from 
300 thousand in 2000 to 490 thousand patients in 2025. Between 2000 and 2025 the 
prevalence rate of mild COPD increases from 5 to 11 per 1000 inhabitants. The 
prevalence rate of moderate COPD increases from 11 to 14. For severe COPD the rate 
increases from 3.0 to 3.9 and for very severe COPD the rate increases from 0.5 to 1.3. 
In absolute numbers the increase is highest in mild COPD, but the largest relative 
increase in prevalence rate is seen in very severe COPD. As a result of the increase in 
COPD prevalence and aging of the COPD population, all-cause mortality rates per 1000 
inhabitants increase in all severity stages. In 2000, total COPD-related health care costs 
are estimated to be 280 million Euros. In 2025 total costs are projected to be 495 million 
Euros. Costs for very severe COPD have the highest relative increase. The sensitivity 
analyses show that the model projections were most sensitive to assumptions about the 
severity distribution of incidence. 
Implementation of H-MIS and IC+Bupr results in more mild and moderate and less 
severe and very severe COPD patients compared to the base-case scenario after 25 
years. Costs per additional quitter are 700 for H-MIS and 2700 for IC+Bupr. Irrespective 
of the duration of implementation, H-MIS generates net savings, which indicates that the 
intervention costs of H-MIS are offset by the savings in COPD-related costs. For 
IC+Bupr savings do not outweigh the interventions costs. For the years 2000 to 2025 the 
costs per life-year gained of implementing IC+Bupr for 10 years are estimated to be 
12000 Euros. 
 
Conclusions: Modelling COPD progression over time proves feasible. The model 
showed that implementation of H-MIS among COPD patients results in better health 
outcomes and is cost saving. Implementation of IC+Bupr has higher costs than savings, 
but is still cost-effective with costs per life-year ranging from 10600 to 24500 depending 
on the duration of implementation. 
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1. Introduction 
 
In order to plan appropriate allocation of health care resources it is important for 
decision-makers to be informed about the future burden and costs of disease in their 
country and the impact of health care interventions on this burden. This is true for COPD 
in particular, because of the rise in morbidity and mortality that is foreseen for the near 
future. 
Projections of the future burden of COPD for different intervention scenarios can be 
made through the use of models. In the past the National Institute of Public Health and 
the Environment (RIVM) and the Institute for Medical Technology Assessment (iMTA) 
have developed a health policy model for COPD that projects the future incidence and 
prevalence of COPD by age, gender and smoking class. The model projects the future 
burden of COPD in terms of mortality, life-years lost, disability adjusted life-years lost 
(DALYs) and COPD-related health care costs. This model has been published (Feenstra 
et al., 2001) and has been used to simulate the impact of anti-smoking campaigns 
directed at the general public on the incidence and burden of COPD in the Netherlands 
(Rutten-van Molken et al., 1999). 
However, this model had a major shortcoming. It did not model the progression of COPD 
once a person was diagnosed with COPD. Therefore the model could not be used to 
study the consequences of any intervention that was specifically directed at COPD 
patients.  
The purpose of the current project was to update and improve the model such that it 
includes the progression of COPD over time, in order to be able to simulate the effects of 
both preventive and therapeutic interventions upon burden and costs of COPD for an 
extended time horizon. More specifically the purpose of the project was: 
1. To improve the existing COPD model by incorporating the distinction between mild, 
moderate, severe and very severe COPD and by quantifying the progression of 
COPD over these states. 
2. To use the improved model to estimate the potential impact of smoking cessation 
programs offered to COPD patients and project their effect on the future burden of 
COPD. 
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2. Update of the existing COPD model 
 
The existing COPD model is a module of the chronic disease model developed by the 
National Institute of Public Health and the Environment (RIVM). This chronic disease 
model is a dynamic multistate lifetable model that has been used to project the health of 
the Dutch population (van Oers, 2002), in order to inform policy makers. The model 
basically consists of a demographic module that is linked to several disease-specific 
modules, among which is the COPD module. 
In contrast to many other models, which follow a cohort of people over time until this 
cohort has died, the chronic disease model is a dynamic population-based model. This 
means that it takes account of annual changes in the demography of the Dutch 
population. These changes are due to ageing, birth, and mortality. It also models 
epidemiological processes, like changes in the prevalence of risk factors and risk-factor-
specific incidence, prevalence and mortality of chronic diseases. When estimating 
mortality, the model takes account of competing death risks, because otherwise COPD 
prevalence would be overestimated. In other words, because the incidence of other 
smoking-related diseases among COPD patients is higher than among the general 
population, COPD patients run a larger risk to die, not only from COPD, but also from 
those other smoking-related diseases. 
 
The existing model is populated with demographic data, data on COPD incidence, 
prevalence and mortality by gender and 5-year age classes, data on smoking 
prevalence and transition rates between the 3 smoking classes. As part of the project 
reported here, these data have been updated to the base year 2000. A brief description 
of the source of these data is given below. 
 
2.1 Demography 
Demographic data were obtained from Statistics Netherlands. They comprised data on 
and prognoses of births and total mortality for each gender and 5-year age class. In 
table A1 of appendix A the population numbers for the base year 2000 are shown by 
gender and 5-year age class.  
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2.2 COPD Incidence, Prevalence and Mortality 
Table A2 in appendix A shows COPD incidence, prevalence and excess mortality by 
gender and 5-year age classes. Incidence data were obtained from 3 GP registration 
systems that cover different parts of the country: 1) the Continuous Morbidity 
Registration of the department of General Practice and Social Medicine of the University 
of Nijmegen (van Weel et al., 2000), 2) the Registration Network Family Practices of the 
University of Maastricht (Knottnerus et al., 1992) and 3) the Transition project of the 
department of Family Practice of the University of Amsterdam (Lamberts et al., 1996). 
Prevalence data were obtained from the first 2 GP registrations. 
Data from these GP registrations were combined and smoothed over age to obtain 
estimates of the incidence and prevalence of COPD in a Dutch general practice in 2000. 
Incidence and prevalence under the age of 45 years were assumed to be the result of 
misclassification and were not included. In all projections that were made, the 2000 age- 
and gender-specific COPD incidence and prevalence rates were used without time 
trends, other than those caused by changes in smoking patterns. 
Mortality rates for COPD patients were estimated as the difference between mortality in 
the general population and mortality among COPD patients (Hoogenveen et al., 1998). 
This difference is called COPD excess mortality and includes the additional risk to die 
from other smoking related diseases. 
 
2.3 Smoking prevalence and transition rates 
Smoking is the major risk factor for COPD. The prevalence of non-smokers, smokers 
and ex-smokers among the Dutch population by gender and 5-year age classes is given 
in table A3. These rates were based on yearly population monitoring studies of Stivoro 
for the time period 1997-2000. Table A4 shows the start-, stop-, and restart rates that 
were used to model changes in smoking prevalence in the Dutch population over time. 
Start rates were calculated based on the change in age-specific prevalence rates of 
never smokers. Stop rates were based on a weighted average of Stivoro data (1998-
1999)  and three Dutch cohort studies (Deeg et al., 1993; Mackenbach et al., 1994; 
Blokstra et al., 1997). They approximated 12-month continuous abstinence rates. Restart 
rates were estimated by combining the smoking prevalence rates of the yearly 
population monitoring studies by Stivoro over the period 1997-2000 with the stop rates 
mentioned above. In the model, trends in smoking over time are a result of age-specific 
prevalence, start, restart and stop rates.  
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2.4 COPD incidence among non-smokers, smokers and ex-smokers 
The incidence of COPD in each smoking class was estimated from the observed age- 
and gender-specific COPD incidence in the GP registrations and the relative risks of 
smokers and ex-smokers to get COPD (US-DHHS, 1990; van Oers, 2002). These 
relative risks, stratified by gender and 5-year age class, are shown in table A5.  
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3. Description of the new COPD model 
 
In order to evaluate the (cost-)effectiveness of interventions specifically directed at 
COPD patients the existing model was extended with COPD progression over time. The 
population of COPD patients above 45 years of age and a FEV1/FVC ratio less than 70% 
was classified by disease severity according to the lung function values in the GOLD-
criteria (GOLD, 2003): mild COPD (FEV1% predicted ≥80%), moderate COPD (FEV1% 
predicted <80% and ≥50%), severe COPD (FEV1% predicted <50% and ≥30%) or very 
severe COPD (FEV1% predicted <30%).   The estimated severity distribution based on 
GP registration data was applied to the COPD prevalence of our base year 2000 and 
used as a starting point. Figure 3.1 describes the structure of the new model.   
 
Smokers
End Base year
t 
Mod
Never smokers
Mild
Sev
Very 
sev
COPD
Mod
Mild
Sev
Very 
sev
COPD
MildVery 
sev
Ex-smokers
ModSev
COPD
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Ex-smokers
ModSev
COPD
MildVery 
sev
Smokers
ModSev
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MildVery 
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Ongoing year
t + 1
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mort
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Figure 3.1: Final structure of the COPD model 
= transition between smoking classes 
= transition between severity stages 
= incidence 
= mortality 
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Each year new patients are diagnosed within COPD severity stages. COPD patients can 
move to a worse severity stage, because of disease progression. Disease progression 
was modelled as annual decline in lung function. Decline in lung function was assumed 
to depend on age, gender, smoking and FEV1% predicted.  The annual decline was 
transformed into a stage transition rate indicating the probability of moving to the next 
severity stage while being in a specific severity stage. Patients may move backwards 
into a less severe stage when they stop smoking and their lung function improves, 
however, the estimated transition rates are very low. Complete recovery from COPD is 
impossible by assumption. Because worse severity stages are associated with a higher 
risk of mortality, mortality rates for the different severity stages were estimated. In 
appendix C the mathematical description of the model is given.  
 
With all these adaptations the new model is able to evaluate interventions in COPD 
patients, that influence disease progression. For example smoking cessation leads to a 
one-time increase in FEV1% predicted and a lower annual decline of FEV1% predicted. 
As a result, transition rates for ex-smokers are lower than for smokers. Because 
mortality is higher in worse COPD severity stages, ex-smokers have a lower COPD 
mortality than smokers. In the remainder of this chapter the new input data are 
described. These data were finalized after discussion with and input from an expert 
panel, which consisted of an epidemiologist, a general practitioner and 2 
pulmonologists.2 Their valuable suggestions and comments gave rise to various 
adaptations of model parameter values, but the final input data are the full responsibility 
of the authors. These data concern the distribution of COPD prevalence and incidence 
by severity, the decline in FEV1% predicted in each COPD severity stage, the 
association between FEV1% predicted and mortality and the COPD related health care 
costs by severity stage. 
 
3.1 Distribution of prevalence by severity  
To estimate the severity distribution of COPD in the Netherlands, we have used two 
different sources of GP-data: data from the Nijmegen Monitoring Project (NMP) and from 
the Institute for research in extramural medicine (EMGO). We have chosen GP 
registrations, because virtually all people in the Netherlands, including those treated by 
                                                
2 Members of the expert panel were dr. Jan Schouten (epidemiologist), dr. Ivo Smeele (general 
practitioner), prof. dr. Emiel Wouters (pulmonologist) and dr. Sonia Buist (pulmonologist) 
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pulmonologists, are registered with a GP practice. Therefore, these data probably best 
represent the Dutch COPD population known to the GP. Moreover, the incidence and 
prevalence data of COPD (see table A2) that go into the model are also based on GP 
registrations. Classification of COPD-severity was based on post-bronchodilator FEV1% 
predicted conform the GOLD-guidelines (GOLD, 2003). 
 
NMP-data 
Firstly, we selected all patients with a physician diagnosis of COPD (code R91/R95) 
and/or asthma (R96) from five general practices in the Nijmegen Monitoring Project 
(NMP): Lent, Oosterhout, Doesburg, Wychen and Berghem (van Weel et al., 2000). 
These general practices are unique, because they keep an electronic record of 
spirometric results. 530 patients had a diagnosis of COPD and 938 had a diagnosis of 
asthma. Of the 530 COPD-patients, only 25 patients also had a diagnosis of asthma. 
From 307 of the 530 COPD patients spirometric data were available. Patients with and 
without spirometry did not differ significantly with respect to age, gender, co-morbidities 
and number of prescriptions of relevant medication for COPD (Table B1 in Appendix B). 
Based on the available information we assumed that the groups with and without 
spirometry were not different.  
 
For each patient, the largest FEV1 value of the two most recent consecutive years with 
measurements in the period 1997-2002 was taken. When post-bronchodilator values 
were not available, pre-bronchodilator values were multiplied by a factor 1.095. This 
factor was computed from the observed difference between pre- and post-bronchodilator 
values in the data. The FEV1% predicted was calculated using the equations of Quanjer 
(Quanjer et al., 1993). Among the 307 COPD patients with spirometric data, 85 patients 
who did not have a FEV1/FVC < 70% and 6 patients younger than 45 years were 
excluded for classification. Results of the classification are shown in table 1 below.  
 
EMGO-data 
Secondly, we have used a database from the EMGO institute of the Free University of 
Amsterdam that contained lung function data on asthma and COPD patients from 25 GP 
practices that participated in a clinical trial (Wijnhoven et al., 2001). All patients with a 
physician diagnosis of either asthma or COPD were asked to participate in the clinical 
trial. 2047 patients met the following inclusion criteria: age 16 to 75 years, capable of 
filling in a Dutch questionnaire, no specific pulmonary disease other than asthma or 
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COPD and absence of any disease in a terminal phase. 1325 patients were willing to 
participate in the trial. The 722 patients, who did not enter the trial, were significantly 
younger and a higher percentage was male (Wijnhoven et al., 2001).  
 
1308 of the 1325 patients had valid lung function measurements at baseline. Of these 
1308 patients 701 either had a physician diagnosis of COPD (n=291) or the distinction 
between asthma and COPD was unknown  (n=410). 153 of the 291 patients with a 
physician diagnosis of COPD also had a diagnosis of asthma, but where included, 
because the incidence and prevalence data used in the model (see table A2) are also 
obtained from GP registrations and might also contain some patients which have both 
diagnoses. FEV1% predicted values were again calculated with Quanjer’s equations 
(Quanjer et al., 1993). In table B2 in the appendix baseline characteristics of the patients 
are shown. 
Patients were classified using the same criteria that were used for the NMP data, 
excluding patients with an FEV1/FVC over 70% and younger than 45 years of age. The 
results are also shown in table 3.1 below.  
 
Table 3.1: Distribution of disease severity among COPD patients known to the GP 
 COPD severity by GOLD criteria, FEV1/FVC<70% 
Percentage (number of patients) 
 Mild 
FEV1% predicted 
>=80% 
Moderate 
FEV1% predicted 
>=50% and <80% 
Severe 
FEV1% predicted 
>=30% and <50% 
Very severe 
FEV1% predicted 
<30% 
NMP 31% (67) 47% (102) 19% (41) 3% (6) 
EMGO 28% (75) 55% (146) 15% (39) 2% (5) 
Total* 28% 54% 15% 3% 
* The final distribution over the four severity stages is based on figure 3.2. 
 
Final severity distribution 
In figure 3.2 the frequency distribution of FEV1% predicted is shown for the combined 
NMP and EMGO-data. The columns show the empirical data, the continuous line the 
fitted normal distribution density function. We tested for log normality, but the normal 
distribution performed better. Therefore we assumed that FEV1% predicted is normally 
distributed. Based on this normal distribution with a mean FEV1% predicted of 68.3% 
(SD 19.9%) we estimated that 28% had mild COPD, 54% had moderate COPD, 15% 
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had severe COPD and 3% had very severe COPD. This severity distribution is used in 
our base-case analysis and applied to each subgroup of COPD patients defined by age, 
gender and smoking class. Next to that, the normal distribution is used to estimated the 
distribution of FEV1% predicted within each COPD stage. 
 
 
Figure 3.2: Distribution of FEV1% predicted of prevalent cases of COPD based on both 
NMP and EMGO data 
 
We assumed that within each COPD stage the distribution function of FEV1% predicted 
was linear, i.e. we approximated the normal distribution function by estimating linear 
functions for each separate severity stage. However, in moderate the curve is not linear, 
because the top of the curve is in this stage. To describe this top, we divided moderate 
into two stages (cut-off point of 68 FEV1% predicted) and fitted linear functions to both 
the stages of moderate COPD patients. 
3.2 Distribution of incidence by severity 
Due to small numbers, the distribution of COPD incidence by disease severity could not 
be estimated reliably from the GP data. Therefore we estimated the distribution of the 
incidence over the severity stages assuming the prevalence being constant between 
2000 and 2001. That is, given the prevalence, disease progression and mortality in 
2000, the incidence should be such, that the distribution of FEV1% predicted in the entire 
COPD population in the year 2001 should not differ from the distribution in the year 
2000, when keeping smoking prevalence rates and population numbers constant. The 
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estimated severity distribution of the incidence (mean=76.4, sd=15.6) was then applied 
in each year after 2000. In table 3.2 the estimated distribution of incidence by disease 
severity is shown. 41% of the newly diagnosed COPD patients has mild COPD, 55% has 
moderate COPD and 4% has severe COPD. There is no incidence in very severe 
COPD. 
 
Table 3.2: Distribution of incidence by severity 
 Mild 
FEV1% 
predicted 
>=80% 
Moderate 
FEV1% 
predicted 
>=50% and 
<80% 
Severe 
FEV1% 
predicted 
>=30% and 
<50% 
Very severe 
FEV1% 
predicted 
<30% 
Incidence 41% 55% 4% - 
 
This distribution of COPD incidence by severity is used in our base-case and applied to 
each subgroup of COPD defined by age, gender and smoking class. 
 
3.3 Transition rates between severity stages 
In the model disease progression and mortality rates determine the average time spent in 
a certain severity stage. Estimates of the transition rates were based on estimates of the 
decline in FEV1% predicted, which depended on age, gender, smoking class (smokers 
and ex-smokers) and absolute FEV1% predicted.  
 
Description of the data 
Our primary source of data on FEV1 decline was the Lung Health Study (LHS), a study 
that was specifically designed to estimate the effect of smoking and smoking cessation 
on lung function decline in COPD patients. For this study 5887 smokers with mild to 
moderate airflow obstruction aged between 35 and 60 years were recruited. Participants 
were equally randomized into 3 intervention groups, 1 receiving an intensive smoking 
cessation program, 1 receiving the same program in combination with  ipatropium and 1 
receiving usual care. In total 66% of the patients followed the smoking cessation 
program. All patients were followed for 5 years. At baseline and during every annual visit 
lung function was measured, a questionnaire was filled out and smoking status was 
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determined by self-report and validated with salivary cotinine assay and exhaled CO 
measurements (Scanlon et al., 2000).  
We have re-analyzed all 5-year follow-up data of the LHS from the 5887 smokers that 
started the LHS. Baseline characteristics  of the study population are shown in table B3. 
Because no effect of ipatropium on decline in lung function was observed in the LHS, we 
used data from all three intervention groups. 
 
Statistical procedure 
We have re-analized these original data using a random effects model with year, 
smoking cessation and the interaction between these two variables, year x smoking 
cessation, as the basic model. Gender, age, age2 and baseline FEV1% predicted 
including all significant interactions were added as explanatory variables. This random 
effects model was used to predict decline in FEV1% predicted by age, gender, smoking 
class (ex-smoker and smoker) and COPD-severity.  
The increase in FEV1% predicted associated with smoking cessation was calculated with 
the same model. The coefficients of the model are shown in table B4. Table 3.3 shows 
the decline in FEV1% predicted and the increase in FEV1% predicted after smoking 
cessation, for various subgroups of COPD patients. 
 
Decline outside the range in the observed age and lung function values in the data was 
based on extrapolation of the same model. As a result, the estimated increase after 
smoking cessation for very severe patients is probably too high.  Therefore we decided to 
use a maximum of 6.5% for the increase after smoking cessation, which was the 75-
percentile of lung function increase among all LHS COPD patients, who quitted smoking 
in the first year3. The increase in lung function associated with smoking cessation can 
cause remission to a better severity stage. Total remission, i.e. recovery from COPD, is 
not possible. 
 
 
 
                                                
3 The LHS study recruited patients with mild or moderate COPD. Over time some of the moderate 
patients progressed to severe COPD. For all patients who quitted smoking, while they were in 
stage severe COPD (n=18), the mean increase in lung function associated with smoking 
cessation was 4.0 % predicted (median= 3.9%) 
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Table 3.3: Decline and increase in FEV1% predicted per year for subgroups 
 Age  Decline Increase after 
smoking 
cessation 
   Smokers Ex-smokers  
Men 45 yr Mild -0.68 -0.30 -1.09 
  Moderate -0.81 -0.43 3.82 
  Severe -0.94 -0.56 6.50 
  Very severe -1.04 -0.66 6.50 
 65 yr Mild -1.08 -0.74 -1.23 
  Moderate  -1.40 -1.05 1.31 
  Severe -1.71 -1.37 3.85 
  Very severe -1.94 -1.59 5.73 
      
Women 45 yr Mild -0.84 -0.47 2.66 
  Moderate -0.97 -0.60 5.38 
  Severe -1.11 -0.73 6.50 
  Very severe -1.21 -0.83 6.50 
 65 yr Mild -1.08 -0.74 0.50 
  Moderate -1.39 -1.05 3.04 
  Severe -1.71 -1.36 5.59 
  Very severe -1.93 -1.60 6.50 
 
No data were available for never-smoking COPD patients. Therefore we assumed that 
the decline among never-smoking COPD patients equals the decline among the ex-
smokers. We thought this is better than assuming that the decline equals the decline 
among never-smokers in the general population, because, after all, these patients do 
have COPD. 
 
Each year the model calculates the new distribution of FEV1% predicted within each 
severity stage. The new distribution is calculated as a result of outflow because of 
disease progression and mortality, inflow because of improvement associated with 
smoking cessation and COPD incidence. The transition rates to a more severe COPD 
stage are calculated with the outflow to a more severe stage (surface under the linear 
curve) as percentage of the total surface under the linear curve in that particular severity 
A Health Policy Model for COPD: Effects of Smoking Cessation  19
stage. The transition rates to a less severe COPD stage associated with smoking 
cessation are calculated with the outflow to a less severe stage (surface under the linear 
curve) as percentage of the total surface under the linear curve in that particular severity 
stage. Transition rates change every year, because of changes in the distribution of 
FEV1% predicted. Transition rates for the first year are shown in table B5.  
 
3.4 Mortality rates by severity  
In order to obtain a well-documented estimate of the relative risk (RR) for all-cause 
mortality per unit change in FEV1% predicted, we performed a meta-analysis on papers 
published between 1970 and 2002, which reported the association between FEV1% 
predicted and all-cause mortality in a general or COPD population. Papers had to meet 
the following in- and exclusion criteria 
• At least 3 years of follow-up 
• Caucasian population 
• Correction for at least age and smoking 
• No correction for dyspnoea and decline in lung function 
• Not in patients hospitalised for a COPD exacerbation 
• Reporting standard errors 
 
For each paper that directly reported the RR per unit of change in FEV1% predicted, we 
calculated the relative change in mortality rate associated with a 10-unit decline in 
FEV1% predicted. For each paper that reported the RR per class of FEV1% predicted we 
first fitted a log-lineair risk function on the data, before we calculated the RR of a 10-unit 
decline in FEV1% predicted. The RRs of all papers were combined into a weighted 
average, using a factor based on the precision of the estimate in each paper as a weight.  
 
We found 17 studies, 11 directly reporting the RR per unit change in FEV1% predicted 
and 6 reporting the RRs by class of FEV1% predicted (Traver et al., 1979; Beaty et al., 
1982; Beaty et al., 1985; Ebi-Kryston, 1988; Postma et al., 1989; Lange et al., 1990; 
Lange et al., 1990; Gray-Donald et al., 1996; Hole et al., 1996; Neas et al., 1998; Hansen 
et al., 1999; Knuiman et al., 1999; Landbo et al., 1999; Hospers et al., 2000; Hospers et 
al., 2000; Pelkonen et al., 2000; Schunemann et al., 2000; Anthonisen et al., 2002; 
Prescott et al., 2002).  
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Only 5 of the 17 studies were done in COPD patients. This resulted in an estimate of the 
RR per 10-unit decline of 1.11 (95% CI 1.10-1.12) for studies in a general population and 
a RR of 1.20 (95% CI 1.16-1.23) for studies in COPD patients. Thus in COPD patients 
each 10-unit decrease in FEV1% predicted increased the mortality risk with 20%. Based 
on this result the following figure was constructed. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Relative Risk of all-cause mortality by FEV1% predicted in COPD, setting the 
RR of an FEV1 % predicted of 100 at 1. 
 
The function in figure 3.3 was used to estimate the relative mortality risk of COPD 
patients by severity stage. All-cause mortality in the model was defined as the sum of 
COPD excess mortality and mortality from other causes. Excess mortality was defined as 
the absolute difference in mortality between COPD patients and persons without the 
disease, given gender and age. Excess mortality includes the mortality due to COPD, but 
also the higher risk on mortality from other smoking-related diseases. We assumed only 
excess mortality to be dependent on lung function.  
We applied the relative risks from figure 4 to calculate the excess mortality rates for each 
severity stage. If we assign an RR of 1 to the mean FEV1% predicted of the mild COPD 
patients, then the RR of moderate, severe and very severe COPD can be calculated 
relative to the risk in mild COPD. Total excess mortality in the first year was used to 
calculate the severity stage specific excess mortality rates as given in table 3.4.  
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Table 3.4: Severity stage specific excess mortality rates in the first year  
per 1000 patients in that specific severity stage 
 Excess mortality rates 
Mild 22.4 
Moderate 35.5 
Severe 54.1 
Very severe 77.4 
 
To calculate excess mortality for a specific severity stage in absolute numbers, the 
mortality rate for that severity stage was multiplied with the number of patients in that 
severity stage.  
Mortality from other causes was assumed not to depend on COPD severity, but only on 
age, gender and smoking, which is the same as in the standard model. 
 
3.5 Costs of COPD by severity 
We have estimated the direct medical costs of COPD in the Netherlands for the year 
2000. Data on health care use were, as much as possible, obtained from representative, 
national registries to get age- and gender-specific data on costs. Costs per unit of 
resource use were also estimated. Resource use was multiplied with unit costs to 
calculate total costs for COPD care in the Netherlands. All costs were valued in Euros 
(price level 2000). When unit costs for other years than 2000 were available, the 
consumer price index was used to correct for inflation. Unit costs are shown in table B6 
in appendix B. Only costs made by COPD patients aged 45 years and over were taken 
into account. Total costs were divided by prevalence to find costs per average COPD 
patient. Finally, these average costs were used to find costs per severity class with the 
help of severity weights and the prevalences per severity stage. 
 
Primary care and specialist care 
The number of times COPD-patients visit their general practitioner during a year was 
obtained from the Confronting COPD Study (Wouters, 2003). In this study conducted in 
8 countries, information on COPD-related health care use and lost productivity was 
obtained by means of telephone interviews. The patient samples for the survey were 
identified by systematically screening geographically stratified samples of households, 
using random digit dialling of telephone numbers (Halpern et al., 2003). Inclusion criteria 
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for the survey were 45 years of age or older, a smoking history of at least 10 years and 
previously diagnosed with COPD, emphysema or chronic bronchitis or chronic bronchitis 
defined by persistent coughing with phlegm or sputum for the last 2 years or more. We 
have only used the data of the 415 Dutch participants. One-fifth of the participants met 
the inclusion criterion of persistent cough with phlegm or sputum for the last two years or 
more, but had not been diagnosed with COPD before.  
55% of the 415 COPD patients did visit their general practitioner during one year. The 
mean number of COPD-related visits was 4.6. This resulted in a mean of 2.56 COPD-
related visits for the overall group of COPD-patients. The costs of a visit to the GP were 
derived from Oostenbrink et al (Oostenbrink et al., 2000). 
According to the same data source, 42% of the COPD-patients visited a medical 
specialist during one year. Mean number of visits was 4.2 (Wouters, 2003). Based on 
this information we estimated that the average number of COPD-related visits to a 
specialist was 1.76 for COPD-patients. Unit costs were obtained from (Oostenbrink et 
al.) . Total costs for primary and specialist care were estimated to be 13 and 26 million 
Euros respectively. 
 
Home care 
Information on use of home care was available from the Patient Panel Chronic Diseases 
(PPCZ), a group of people with different chronic diseases including COPD (Heijmans et 
al., 2003). The total Panel of more than 2000 patients includes a group of 310 patients 
with physician-diagnosed COPD, 46% female with a mean age of 65 years old. The 
physician-diagnosis was not validated by spirometry. 
According to the PPCZ the percentage of COPD-patients using home care (help with 
household duties) was 17% during one year. In the general population this percentage 
was 4%. Therefore we assumed that 13% of the use of home care was COPD-related. 
From the PPCZ no data were available on the number of hours home care. We assumed 
an average of 3 hours a week, which is the mean number of hours of home care for a 
65-year old receiving home care. (Stevens et al., 2001). The unit costs of home care are 
obtained from Oostenbrink et al (Oostenbrink et al., 2000). Total COPD-related costs for 
home care were estimated to be 54 million Euros. 
 
Inpatient care 
The number of admissions to hospitals, day-care in hospitals and the number of 
inpatients days for COPD, were obtained from the National Medical Registration (LMR) 
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(LMR, 2000). This registration covers almost 100% of all Dutch hospitals. It contains 
information on day-care treatment, hospital admissions, hospital days and clinical 
procedures. Except for Salem and Davos all Dutch asthma centres are present in this 
registration. We selected the ICD-9 (International Classification of Disease) codes 490-
492, 494 and 496 to represent COPD. Only the admissions with COPD as the main 
reason for admission were taken into account. In 2000 total number of inpatients days 
for patients 45 years and older was 959 for day-care treatment and 277663 for clinical 
days. The mean length of stay per admission was 14.3 days. In the tables B8 and B9 the 
total number of admissions, days for day-care treatment and hospital days are shown for 
different age- and gender classes. Unit costs of a hospital day and a day-care treatment 
day were obtained from Oostenbrink et al (Oostenbrink et al.). Total costs for day-care 
treatment were estimated to be 170 thousand Euros, while total costs for inpatient 
hospital days were almost 75.3 million Euros.   
Data on costs for COPD related to nursing and residential care facilities were obtained 
from a cost of illness study from Polder et al. (Polder et al., 2002). Costs were only 
available for COPD and asthma together. Because we only took into account costs for 
patients above 45 years old, we assumed that 90% of the costs were due to COPD and 
10% to asthma. Total costs for COPD were thus estimated to be 34 million Euros. In 
table B9 total costs for different age-and gender classes are shown.  
 
Medication 
To obtain the percentage of COPD-patients receiving an influenza vaccination annually, 
we have used data from the evaluation of the national influenza vaccination campaign 
(Tacken et al., 2000). In 2000 75% of the patients with pulmonary diseases (no further 
subdivision was given) received an influenza vaccination. We assumed this percentage 
to be the same for COPD. The costs of an influenza vaccine were obtained from the 
Pharmacotherapeutic Kompas (Kuy van der et al., 2000). Unit costs for one vaccination 
were calculated adding half the price of a visit to the general practitioner to the price of 
the vaccine.  
Medication costs included 4 categories of medications: corticosteroids (H02), 
antibacterials (J01), anti-asthmatics (R03) and cough- and cold-medications (R05). The 
R03 group contains most of the relevant inhalation medication, such as 
glucocorticosteroids, anticholergics, ß-sympathicomimetica etc. From the Foundation for 
Pharmaceutical Statistics (SFK) the total number of prescriptions and total costs for each 
medicine in the 4 selected groups for the year 2000 in the Netherlands were obtained 
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(SFK, 2000). Total prescriptions were age- and gender-specific. No information on 
prescriptions per diagnosis was available in the SFK-data. Therefore we selected the 
same groups of medications in the LINH, a countrywide registration network of 90 
general practices (LINH, 2000), that records both prescriptions and the diagnosis 
associated with the prescription. For each single medication within the selected groups, 
the ratio of the number of prescriptions for COPD to the total number of prescriptions 
was calculated. These ratios from the LINH were used to estimate for each medication in 
the SFK data, the number of prescriptions in every age-and gender-class in 2000 that 
was due to COPD. Table B10 shows the total costs for different age- and gender 
classes. Total costs for medications were 60.4 million of which more than 90% were due 
to the anti-asthmatics (R03). 
 
The use of oxygen therapy was estimated based on information from the research 
program “Thuiszorgtechnologie” from the Netherlands Organisation for Health Research 
and Development (ZonMW, 1999). In this source the number of patients with oxygen 
therapy at home, irrespective of their diagnosis, was estimated to be 10 000 in 1999. In 
a study from Kampelmacher et al. 70% of a random sample of clients of an oxygen 
company had a diagnosis of COPD (Kampelmacher et al., 1998). Therefore we assumed 
that about 70% of the total number of patients receiving oxygen therapy at home, was 
COPD-patient, which resulted in a total of 7000 COPD-patients using oxygen at home in 
the Netherlands.  
Unit costs for oxygen were 4.24 Euros per day per patient based on an agreement 
between the Health Insurance Companies and the oxygen supplying companies. Total 
costs were estimated to be almost 11 million Euros.  
 
Surgery 
Ten Vergert et al. performed an evaluation study to the effectiveness of lung 
transplantation (Ten Vergert, 1996). In the study period 57 lung transplantations were 
performed of which 40,3% were performed on patients with a diagnosis of COPD. 
Therefore we assumed that of all performed lung transplantations roughly 40% is due to 
COPD. According to Eurotransplant 17 lung transplantations took place in the 
Netherlands in 2000 (Eurotransplant, 2000). We estimated that 7 transplantations were 
performed on COPD-patients. Unit cost for lung transplantation were obtained from a 
study of Al et al (Al et al., 1998). Total costs of lung transplantation were 1.2 million 
Euros for the year 2000.  
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Total costs and costs by severity 
Total direct medical costs for COPD (above 45 years of age) were estimated to be 280 
million Euros, 915 Euros for an average COPD patient (table 3.5).  
 
Table 3.5: Total cost in million Euros for COPD patients aged 45 years and older 
(n=305831) in 2000 
 Total costs per patient Total costs in million 
Euros 
Day-care treatment in hospital 0.55 0.169 
Inpatient hospital care 246 75.4 
Nursing home and residential care  112 34.3 
   
Home care 177 54.1  
General practitioner 42 13.0  
Medical specialist 88 26.8 
   
Influenza vaccination 11 3.45 
Medication 198 60.4 
Oxygen therapy 35 10.8 
   
Lung transplantation 4 1.25 
Total 915 280 
 
Some data on resource use, such as day-care treatment in hospital, inpatient hospital 
care, nursing home and residential care and medication, were age and gender specific 
data. If age and gender specific data on resource use were not available, total costs per 
age and gender class were estimated by multiplying the mean costs per patient with the 
number of COPD patients in that specific age and gender class. Finally for each age and 
gender class total costs were estimated by summing all age and gender specific costs 
for the different forms of health care use.  
It was not possible to estimate resource use per severity stage. Therefore we have used 
a Swedish study to obtain ratios for the costs of a patient with moderate, severe or very 
severe COPD compared to the costs of a patient with mild COPD (Jansson et al., 2002). 
We used these ratios to assign total costs within each age- and gender class to the 
different severity stages (table B11). An exact description of the calculation of costs per 
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patient is given in appendix B11. In table 3.6 the average costs per patient for the 
different severity stages are shown. 
 
Table 3.6: Costs in million Euros per severity stage 
Severity stage Ratio Patients (n) Costs (Euros per 
patient) 
Total costs in 
million Euros 
Mild 1.0 81200 277 22.5 
Moderate 2.22 169000 616 104 
Severe 7.51 47300 2080 98.6 
Very severe 24.67 7900 6840 54.3 
 
3.6 Sensitivity analyses 
To study the robustness of the outcomes of the projections, we have done extensive 
one-way sensitivity analyses on the severity distribution of COPD prevalence and 
incidence, on lung function decline, on the one-time increase in lung function after 
smoking cessation, on the lung function decline among never-smokers and on the 
association between lung function and mortality. 
 
Sensitivity analysis on the severity distribution of COPD prevalence 
Instead of using the same base-case severity distribution for each age class, we have 
assigned the severity distribution as shown in figure 3.2 to a population with the age of 
66, which is the mean age of the group of COPD patients on which this distribution was 
estimated. For each year younger than 66, the distribution shifts 0.5% predicted to the 
right and for each year older than 66 it shifts 0.5% to the left. 
 
Sensitivity analyses on the severity distribution of COPD incidence 
Instead of the incidence as reported in table 1, we have assumed a severity distribution 
that mirrors the severity distribution of the prevalence, i.e. 28% of the incidence in mild 
COPD, 54% in moderate COPD, 15% in severe COPD and 3% in very severe COPD. In 
addition we have studied the impact of assuming that 60% of the incidence occurs in 
mild COPD and 40% in moderate COPD. Both assumptions are extremes, the real 
distribution is somewhere in between and probably close to what we have estimated in 
section 3.2.                                   
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Sensitivity analyses on decline in lung function 
We did a sensitivity analysis assuming that the decline in FEV1% predicted was 10% 
lower than predicted from the LHS data and a sensitivity analysis assuming that the 
decline in FEV1% predicted was 10% higher than predicted from the LHS data. 
 
Sensitivity analysis on the one-time increase in lung function after smoking cessation 
We have modelled disease progression without assigning the one-time increase in lung 
function to the COPD patients who stop smoking. However, those who stop smoking 
keep the reduction in lung function decline.  
 
Sensitivity analysis on the lung function decline among never smokers. 
Instead of assuming that the lung function decline among never smokers is equal to the 
decline among ex-smokers, we have assumed that the decline is equal to the decline 
among smokers. 
 
Sensitivity analysis on the association between lung function and mortality 
Because our meta-analysis had indicated a significant deviation from the exponential 
model, we have applied the log-squared model that best fitted the data we had on the 
association between lung function and mortality. This implies that the RR per 10-units 
decrease in FEV1% pred is 1.101 when the mean FEV1% pred is 100% and that this RR 
increases with 2.1% per 10-units decrease in mean FEV1% pred. In other words, as lung 
function declines the mortality risk increases more than exponentially. 
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4. Base-case and smoking cessation scenarios 
 
4.1 Base-case scenario 
In the base-case scenario we will project the change in COPD severity over time when 
the age, gender and smoking class specific lung function decline in each COPD severity 
class is applied to the severity distribution of COPD in 2000. In the base-case scenario 
the smoking cessation rates remain unchanged at the level estimated for 2000 and 
presented in table A4. 
The results of this base-case scenario will be reported in terms of: 
• Absolute numbers of COPD patients in each severity stage over time, stratified by 
gender, age and smoking class 
• Prevalence rates by COPD severity stage over time, stratified by gender, age and 
smoking class  
• The proportional distribution of COPD severity over time, stratified by gender, age 
and smoking class 
• The costs of COPD by severity stage over time 
• Mortality rates by COPD severity stage over time 
 
4.2 Smoking cessation scenarios 
In addition to the base-case scenario we will simulate 2 smoking cessation scenarios. In 
the first scenario we will assume that an additional proportion of 25% of all smoking 
COPD patients are offered minimal counselling by the general practitioner (H-MIS). 
Hence, we assume that 25% of all smoking COPD patients get the higher smoking 
cessation probability of the H-MIS4, whereas 75% of all smoking COPD patients keep 
the current cessation probability which is on average 4.73% for both men and women. In 
the second scenario we will assume that an additional 25% of all smoking COPD 
patients are offered intensive counselling in combination with bupropion (IC+Bupr). As in 
the previous scenario, we assume that 25% of all smoking COPD patients get the higher 
                                                
4 The higher cessation probability was calculated by multiplying the current cessation probability 
in each 5-year age and gender class (Table A4) with the ratio of the cessation probability of the 
H-MIS and the overall current practice cessation probability of 4.73%. I.e. if the current cessation 
probability for 60-64 year old men is 0.049, than the probability when offered the H-MIS is 0.049 * 
(0.072/0.0473) = 0.082. 
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smoking cessation probability of IC+Bupr whereas 75% keeps the current cessation rate. 
Both scenarios are implemented for a period of either 1 year, 10 years or 25 years. In 
both scenarios we will assume that the interventions are equally effective across COPD 
severity categories. 
A literature search learned that there are relatively few randomised clinical trials on the 
effects of smoking cessation interventions in patients with COPD (Pederson et al., 1991; 
Crowley et al., 1995; Scanlon et al., 2000; Tashkin et al., 2001). There was no study on 
the effects of H-MIS in COPD and only 1 study on the effects of IC+Bupr in COPD 
(Tashkin et al., 2001), but that study did not report 12 month continuous abstinence 
rates. There are 2 Dutch randomised clinical trials on smoking cessation interventions in 
COPD ongoing (co-ordinators: dr. Van der Palen and prof.dr. Van Schayck), but results 
have not yet been published. Therefore we have decided to use estimates of the 
effectiveness of H-MIS and IC+Bupr that were obtained among smokers in general, 
regardless of whether or not they had a smoking-related disease. 
 
Table 4.1 shows the cessation rates and the intervention costs of H-MIS and IC+Bupr. 
Cessation rates were estimated using 12 months continuous abstinence rates as found 
in a Dutch randomised controlled clinical trial for the H-MIS (Pieterse et al., 2001) and 
reported in previous reviews (Willemsen et al., 2003) and meta-analysis for IC+Bupr 
(Hughes et al., 2002). Intervention costs were based on bottom up estimates of resource 
use and costs per unit, and refer to direct medical costs (Feenstra et al., 2003). 
Estimates of resource use were based on practice guidelines and the original clinical 
trials from which the effectiveness data were taken (Feenstra et al., 2003). Hence these 
costs reflect the costs of an optimal implementation of the two smoking cessation 
interventions, which is in line with the effectiveness figures. All costs were expressed in 
Euros at the price level of 2000. 
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Table 4.1: 12 months continuous abstinence rates (± 95% CI) and intervention costs of 
H-MIS and IC+Bupr. 
 12-months continuous 
abstinence 
95% IC Source Intervention costs 
in Euros 
H-MIS 7.9%* 4.7-11.1 1 Dutch RCT 21 
IC+Bupr 17.2% 14.0-20.4 Cochrane review: 
4 RCTs 
334 
* Cessation rate in trial: 8.2%. 9% used H-MIS in combination with nicotine gum. Cessation rate for minimal 
GP counselling: 8.2-(0.09*11.0)/0.91=7.9% 
   
The results of these smoking cessation scenarios will be reported in terms of: 
• The additional number of COPD patients who stop smoking 
• The number of life years gained 
• The number of QALYs gained 
• Savings in COPD related costs associated with a one-time increase in lung function 
and a subsequent reduced decline of lung function because of smoking cessation 
• Additional costs per additional quitter 
• Additional costs per life year gained 
• Additional costs per QALY gained  
 
In the latter 2 incremental cost-effectiveness ratios the costs include the intervention 
costs minus the above-mentioned savings.  
To calculate QALYs the life-years were corrected for the quality of life during these 
years. However, we were not able to identify a single study that has reported QALY-
weights or values by COPD severity stage for all stages simultaneously. Therefore we 
transformed two existing values and their confidence intervals for mild-moderate and 
severe COPD obtained from expert opinion to values for the four GOLD severity stages: 
mild (0.9), moderate (0.8), severe (0.6) and very severe (0.3) (Stouthard et al., 1997). As 
a consequence gain in QALYs should be interpreted with caution. It is merely reported 
for illustrative reasons. 
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5. Results: projections for the base-case scenario 
 
5.1 Prevalence of COPD  
 
Prevalence of COPD by gender 
In figure 5.1 the development of the number of COPD patients from the years 2000 to 
2025 is shown for men and women. The absolute number of COPD patients increases 
both in men and women, but the increase is higher for women. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Projection of number of COPD patients over time 
 
For men the prevalence rate for COPD increases from 24 per 1000 in 2000 to 33 per 
1000 in 2025, which is an increase of 37%.  For women the prevalence rate increases 
from 15 per 1000 in 2000 to 27 per 1000 in 2025, which is an increase of 84%. The 
prevalence rate of COPD for the total population increases with 55%, from 19 per 1000 
to 30 per 1000. Age-specific prevalence rates for the years 2000 and 2025 are shown in 
appendix D, table D1. The age distribution of the COPD population in the Netherlands 
shifts towards older ages.  
 
Prevalence of COPD by smoking class 
In figure 5.2a and 5.2b the model projections for the proportional distribution of male 
COPD patients over smoking classes by age is shown for the years 2000 and 2025. In 
men the total proportion of smoking COPD patients decreases from 49.8 to 44.1%, while 
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the proportion of ex-smoking COPD patients increases from 45.8 to 50.0%. The 
decrease in the proportion of smokers is mostly due to a combination of aging of the 
COPD population and an increase in the proportion of ex-smokers in the older age 
classes in 2025 compared to 2000. When figure 5.2.a and 5.2.b are compared, a clear 
decrease in the proportion of smoking COPD patients in the last 3 age groups can be 
seen. Among the male COPD patients aged 75 years and older 30% is smoking in 2025 
compared to 44% in 2000. Partly this reflects cohort effects, with new generations of 
men having lower smoking prevalence. Partly this reflects continued cessation at old 
ages, with restart rates in the model being zero for these ages.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2a: Distribution of male COPD patients by smoking class in 2000 
 
 
 
 
 
 
 
 
 
 
Figure 5.2b: Distribution of male COPD patients by smoking class in 2025 
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For female COPD patients the change in the proportional distribution of smoking by age 
over time is shown in the figures 5.3a and 5.3b. The proportion of ex-smokers rises from 
31.6% in 2000 to 39.3% in 2025. The proportion of smokers stays constant, 49.4 to 
49.9%, while the proportion of never smokers decreases from 19.0 to 10.8%. Among the 
female COPD patients of 75 years and over 34% is smoking in 2025 compared to 37% 
in 2000. The percentage of never smokers in female COPD patients aged 75 years and 
older falls from 31% in 2000 to 16% in 2025. Probably, this mostly reflects cohort effects.  
 
 
 
 
 
 
 
 
 
 
Figure 5.3a: Distribution of female COPD patients by smoking class in 2000 
 
 
 
 
 
 
 
 
 
 
Figure 5.3b: Distribution of female COPD patients by smoking class in 2025 
 
 
Prevalence of COPD by severity 
The total number of patients in all the four severity stages increases between the year 
2000 and the year 2025 for both men and women (Figure 5.4 and 5.5).  
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Figure 5.4: Projection of the number of patients within each severity stage among men 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Projection of the number of patients within each severity stage among 
women 
 
In table 5.1 the prevalence rates per severity stage and the proportional distribution over 
severity stages are shown. Age and gender specific prevalence rates are shown in table 
D2 of the appendix. 
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Table 5.1: Prevalence rates per severity stage (number per 1000 in the general 
population) 
 Men Women 
 2000 2025 2000 2025 
Mild 6.4 11.8 3.9 9.6 
Moderate 13.3 15.6 8.1 12.7 
Severe 3.7 4.2 2.3 3.6 
Very severe 0.6 1.4 0.4 1.2 
Total 24.0 32.9 14.7 27.0 
 
The prevalence rate of very severe COPD shows the largest relative increase between 
2000 and 2025 both for men, 119%, and for women, 221%. In table 5.2 the severity 
distributions for the year 2000 and 2025 are given. 
 
Table 5.2: Distribution of COPD patients over severity stages (in%) for the year 2000 
and 2025 
 Men Women 
 2000 2025 2000 2025 
Mild 27 36 27 35 
Moderate 55 47 55 47 
Severe 15 13 15 13 
Very severe 3 4 3 5 
 
Both for men and women the number of mild and very severe patients as percentage of 
the total number of COPD patients, increases. In appendix D, figure D1, the proportion of 
COPD patients in each severity stage over time is shown.  
 
5.2 Mortality 
 
In table 5.3 the model projections for the number of deaths from all causes among 
COPD patients in the year 2000 and the year 2025 are shown.  
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Table 5.3: Number of deaths from all causes among COPD patients  
 Men Women 
 2000 2025 2000 2025 
     
Mild 3300 7200 1700 4700 
Moderate 8200 10900 4300 7400 
Severe 2800 3800 1500 2700 
Very severe 600 1600 300 1200 
Total 14900 23500 7900 16000 
 
The absolute number of deaths increases with 58% among men and 104% among 
women. This is largely due to the increase in COPD prevalence and aging of the COPD 
population. The proportion of COPD patients dying per year changes little over time. In 
2000 7.9% of the male COPD patients died compared to 8.7% in 2025. Among women 
this percentage changes from 6.7% in 2000 to 7.2% in 2025. 
 
In figure 5.6 all-cause mortality as percentage of the total number of COPD patients per 
severity stage is shown for the year 2000. Mortality in the total group of COPD patients 
and mortality in the general population (including the COPD population) with the same 
age- and gender distribution as the COPD population are added for comparison.  
Compared to mortality in the general population mortality in the COPD population is 2.0 
times higher among men and 2.5 times higher among women. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: Total mortality as percentage of the total number of patients per severity 
stage in the year 2000 
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These percentages increase little over time. In 2025 the percentages for men changed 
to 7.4, 8.6, 11 and 14 for mild, moderate, severe and very severe COPD, respectively. 
For women the percentages changed to 5.9, 7.1, 9.3 and 12. 
In table 5.4 mortality rates per severity stage are shown.  
 
Table 5.4: All-cause mortality and excess mortality rates in each of the severity stages 
per 1000 COPD patients  
 Mild Moderate Severe Very severe 
All-cause 
mortality 
    
Men     
2000 17.4 43.5 15.0 3.1 
2025 26.6 40.4 14.1 5.9 
     
Women     
2000 14.2 36.8 13.2 2.8 
2025 20.8 33.2 12.2 5.4 
     
Excess 
mortality 
    
Men     
2000 5.9 19.6 8.4 2.0 
2025 8.4 17.2 7.2 3.4 
     
Women     
2000 6.0 19.7 8.4 2.0 
2025 8.1 16.8 7.4 3.7 
 
The mortality rates in moderate en severe COPD decrease, while the mortality rates in 
mild and very severe COPD increase, largely because the percentage of mild and very 
severe COPD patients in the total COPD population increases.  
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5.3 COPD-related costs 
 
Total costs of care for COPD in 2000 are estimated to be 280 million Euros. In 2025 
costs are projected to be 495 million Euros, an increase of 77%. In figure 5.6 
undiscounted total costs over time are shown for men and women separately. The 
increase reflects the increase in prevalence rates, combined with the change in the 
proportions of the different severity stages. In 2000 the mean costs for COPD per patient 
are 910 Euros, while the mean costs per patient are 1000 Euros in 2025. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7: Total costs due to COPD over time  
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In figure 5.8 total costs for each severity stage are shown. For men costs for mild COPD 
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for mild COPD among women increase with 160%, for moderate COPD with 64%, for 
severe COPD with 66% and for very severe COPD with 241%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8: Total costs by severity stage 
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6. Results: sensitivity analysis for the base-case scenario 
 
In this section we describe how sensitive the estimates of COPD prevalence, mortality 
and costs are to changes in the input variables and assumptions. We computed model 
projections for 8 different variations to the base-case. The different variables and model 
assumptions tested and their values were described in section 3.6.  
 
6.1 Prevalence of COPD 
 
Prevalence of COPD by gender 
In 2000 the total number of COPD patients is 305 800, 188 400 men and 117 400 
women. In table 6.1 total number of COPD patients in 2025 are shown for the different 
sensitivity analyses compared to the base-case scenario.  
 
Table 6.1: Sensitivity analyses on the total number of COPD patients in 2025  
 Men Women Total 
Base-case 269 900 224 400 494 300 
    
1. Distribution of prevalence over severity stages 
differs by age class 
273 700 227 500 501 200 
2. Severity distribution of incidence as prevalence 259 600 215 800 475 400 
3. Severity distribution of incidence: 60% in mild, 40% 
in moderate 
280 500 233 400 514 000 
4. Decline in FEV1% pred as base-case –10% 271 100 225 500 496 600 
5. Decline in FEV1% pred as base-case  +10% 268 600 223 300 491 900 
6. No increase in FEV1% pred after smoking cessation 268 900 223 800 492 700 
7. Never smoker has decline smoker 269 700 224 200 493 900 
8. More than exponential association between lung 
function and mortality  
268 900 223 500 492 400 
 
The prevalence of COPD in 2025 is most sensitive to the assumptions that we made 
about the severity distribution of the incidence of COPD. The two different assumptions 
about the distribution of incidence by severity of COPD (sensitivity analyses 2 and 3) 
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represent 2 extremes giving the lowest and the highest number of COPD patients. The 
prevalence numbers are either 4% lower or 4% higher than in the base-case. Estimates 
of total COPD prevalence are quite robust for the changes in the severity distribution of 
the COPD prevalence, the decline in lung function and the association between lung 
function and mortality.  
 
Prevalence of COPD by smoking class 
For all sensitivity analyses the proportional distribution of COPD patients by smoking 
class does not change with more than 0.3% of the base-case values (see appendix E, 
table E1). For base-case and all sensitivity analyses 44% of all male COPD patients is 
smoker at year 2025, 6% is never smoker and 50% is ex-smoker. Among female COPD 
patients the distribution over smoking classes also stays the same after 25 years for 
base-case and all sensitivity analyses; 50% is smoker, 11% is never smoker and 39% is 
ex-smoker. 
 
Prevalence of COPD by severity 
For the year 2000 the base-case scenario and all sensitivity analyses except one, have 
the same starting distribution of COPD patients over severity stages, 27% mild COPD, 
55% moderate COPD, 15% severe COPD and 3% very severe COPD. Only the 
sensitivity analysis on the severity distribution of prevalence (sensitivity analysis 1) 
shows another starting distribution for the year 2000: 23% mild COPD, 54% moderate 
COPD, 19% severe COPD and 4% very severe COPD. However, as is shown in table 
6.2 this does not very much affect the severity distribution in 2025. 
In table 6.2 prevalence rates per severity stage are shown for men for the year 2025 for 
the different sensitivity analyses. 
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Table 6.2: Sensitivity analyses on the prevalence rates per severity stage for men in 
2025 
 Mild Moderate Severe Very 
severe 
Base-case 11.8 (36%) 15.6 (47%) 4.2 (13%) 1.4 (4%) 
     
1. Distribution of prevalence 
over severity stages differs by 
age class 
12.2 (37%) 15.8 (47%) 4.1 (12%) 1.3 (4%) 
2. Severity distribution of 
incidence as prevalence 
8.1 (26%) 14.3 (45%) 6.6 (21%) 2.8 (9%) 
3. Severity distribution of 
incidence: 60% in mild, 40% in 
moderate 
17.4 (51%) 14.7 (43%) 1.4 (4%) 0.7 (2%) 
4. Decline in FEV1% pred as 
base-case –10% 
12.1 (37%) 15.9 (48%) 4.0 (12%) 1.1 (3%) 
5. Decline in FEV1% pred as 
base-case  +10% 
11.6 (35%) 15.2 (47%) 4.3 (13%) 1.7 (5%) 
6. No increase in FEV1% pred 
after smoking cessation 
11.5 (35%) 15.5 (47%) 4.3 (13%) 1.5 (5%) 
7. Never smoker has decline 
smoker 
11.8 (36%) 15.5 (47%) 4.2 (13%) 1.4 (4%) 
8. More than exponential 
association between lung 
function and mortality  
11.7 (36%) 15.6 (47%) 4.2 (13%) 1.3 (4%) 
 
Again, the assumptions about the severity distribution of the incidence have the highest 
impact on the severity distribution of COPD prevalence in 2025. If the severity 
distribution of incidence is assumed to be equal to the severity distribution of the COPD 
prevalence in 2000, the percentages of mild, moderate, severe and very severe COPD 
patients in 2025 are 26, 45, 21, and 9% compared to 36, 47, 13 and 4% in the base-
case. If the severity distribution of incidence is assumed to be 60% in mild and 40% in 
moderate, the percentages of mild, moderate, severe and very severe COPD patients in 
2025 are 51, 43, 4 and 2% respectively. 
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In table 6.3 prevalence rates per severity stage are shown for women for the year 2025. 
 
Table 6.3: Sensitivity analyses on the prevalence rates per severity stage for women in 
2025 
 Mild Moderate Severe Very 
severe 
Base-case 9.6 (35%) 12.7 (47%) 3.6 (13%) 1.2 (5%) 
     
1. Distribution of prevalence 
over severity stages differs by 
age class 
9.9 (36%) 12.8 (47%) 3.5 (13%) 1.2 (4%) 
2. Severity distribution of 
incidence as prevalence 
6.6 (25%) 11.6 (45%) 5.5 (21%) 2.4 (9%) 
3. Severity distribution of 
incidence: 60% in mild, 40% in 
moderate 
14.0 (50%) 12.1 (43%) 1.2 (4%) 0.7 (2%) 
4. Decline in FEV1% pred as 
base-case –10% 
9.8 (36%) 13.0 (48%) 3.4 (13%) 1.0 (4%) 
5. Decline in FEV1% pred as 
base-case  +10% 
9.3 (35%) 12.4 (46%) 3.7 (14%) 1.5 (5%) 
6. No increase in FEV1% pred 
after smoking cessation 
9.3 (35%) 12.6 (47%) 3.7 (14%) 1.3 (5%) 
7. Never smoker has decline 
smoker 
9.5 (35%) 12.6 (47%) 3.6 (13%) 1.3 (5%) 
8. More than exponential 
association between lung 
function and mortality  
9.4 (35%) 12.7 (47%) 3.6 (13%) 1.2 (4%) 
 
For women the sensitivity analyses on the severity distribution of the incidence also gave 
the highest deviation from the base-case scenario. If the severity distribution of the 
incidence is assumed to be equal to the severity distribution of the prevalence, the 
percentage of mild, moderate, severe and very severe COPD patients in 2025 is 25, 45, 
21, and 9 compared to 35, 47, 13 and 5 in the base-case. If the severity distribution of 
incidence is assumed to be 60% in mild and 40% in moderate, the percentage of mild, 
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moderate, severe and very severe COPD patients in 2025 is 50, 43, 4 and 2 
respectively.  
As expected, sensitivity analysis 2, shows a shift towards the more severe stages. 
Sensitivity analysis 3 moves the severity distribution over time towards the less severe 
stages. The other sensitivity analyses do not have much influence on the severity 
distribution. 
 
6.2 Mortality 
 
In table 6.4 the mortality rates per 1000 COPD patients for the different severity stages 
are shown. For example the severe COPD mortality rate is calculated as the number of 
patients with severe COPD that have died per 1000 COPD patients (not per 1000 
patients with severe COPD). 
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Table 6.4: Sensitivity analyses on the all-cause mortality rates per 1000 COPD patients 
for the different severity stages 
  Mild Moderate Severe Very 
severe 
Base-case Men 26.6 40.4 14.1 5.9 
 Women 20.8 33.2 12.2 5.4 
      
1. Distribution of prevalence over 
severity stages differs by age class 
Men 
Women 
27.0 
21.1
40.2 
32.8 
13.8 
11.9 
5.8 
5.3 
      
2. Severity distribution of incidence as 
prevalence 
Men 
Women 
18.3 
14.4
37.2 
30.5 
21.5 
18.5 
11.4 
10.3 
      
3. Severity distribution of incidence: 
60% in mild, 40% in moderate 
Men 
Women 
39.1 
30.5
38.3 
31.4 
4.9 
4.5 
3.1 
3.0 
      
4. Decline in FEV1% pred as base-
case –10% 
Men 
Women 
27.3 
21.4
41.5 
34.0 
13.4 
11.7 
4.7 
4.4 
      
5. Decline in FEV1% pred as base-
case  +10% 
Men 
Women 
26.0 
20.4
39.5 
32.3 
14.6 
12.7 
7.1 
6.5 
      
6. No increase in FEV1% pred after 
smoking cessation 
Men 
Women 
25.7 
20.2
40.2 
33.0 
14.7 
12.7 
6.6 
6.0 
      
7. Never smoker has decline smoker Men 26.6 40.4 14.2 6.0 
 Women 20.7 33.0 12.4 5.6 
      
8. More than exponential association 
between lung function and mortality  
Men 
Women 
26.8 
21.1
40.0 
32.7 
14.3 
12.5 
6.1 
5.7 
 
Again mortality rates change the most for the sensitivity analyses where the distribution 
of incidence is varied. The probability of dying while being in a specific severity stage 
stays rather constant (see table E3), so a rise in for example the severe COPD mortality 
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rate, is a result of an increase of the proportion of COPD patients in that severity stage 
compared to the base-case scenario. 
For the base-case scenario the percentage of COPD patients dying in 2025 is 8.7% for 
men and 7.2% for women. Outcomes of the sensitivity analyses range between 8.2 and 
9.2% for men and 6.7 and 7.7% for women (see table E2).  
Except for one sensitivity analysis, all analyses show that the percentage of COPD 
patients dying in each severity stage in 2025 (obtained by dividing number of deaths in a 
specific severity stage by total number of patients in that severity stage), does not differ 
by more than 5% from the base-case. Only the sensitivity analysis where a steeper than 
exponential association between lung function and mortality is assumed, gives a higher 
mortality percentage in the very severe stage:  15.1% compared to 14.2% among men 
and 12.9% compared to 12.0% among women (table E3).   
 
6.3 COPD-related costs  
 
Total costs for the base-case scenario rise from 280 million Euros in 2000 to 495 million 
Euros in 2025. In table 6.5 total costs in 2025 for the different sensitivity analyses are 
shown. 
 
Table 6.5: Sensitivity analyses on the total costs due to COPD in million Euros in 2025 
 Men Women Total 
Base-case 248 247 495 
    
1. Distribution of prevalence over severity stages differs by 
age class 
249 247 496 
2. Severity distribution of incidence as prevalence 348 343 691 
3. Severity distribution of incidence: 60% in mild, 40% in 
moderate 
173 175 348 
4, Decline in FEV1% pred as base-case –10% 232 231 464 
5. Decline in FEV1% pred as base-case  +10% 264 263 527 
6. No increase in FEV1% pred after smoking cessation 258 256 514 
7. Never smoker has decline smoker 250 251 500 
8. More than exponential association between lung function 
and mortality  
246 245 492 
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The sensitivity analysis where the severity distribution of the incidence is assumed to be 
equal to the severity distribution of the prevalence results in 40% more costs than the 
base-case scenario. The assumption that the incidence is 60% in mild and 40% in 
moderate projects 30% lower costs than the base-case. Costs per severity stage are 
shown in table E4. When lung function decline is either 10% lower or 10% higher than 
predicted from the LHS data, the costs are 6% lower or higher than the base-case.  
 
Conclusion for the sensitivity analyses 
From these sensitivity analyses it can be concluded that estimates of COPD prevalence, 
mortality and costs are most sensitive to the assumption we had to make on the severity 
distribution of COPD incidence.  
If the severity distribution of COPD incidence is assumed to be the same as the severity 
distribution of COPD prevalence, the total number of COPD patients will be lowest. With 
this assumption a relative high percentage of yearly incident cases occurs in severe and 
very severe COPD. This results in a higher prevalence of severe and very severe 
COPD, which in turn results in a higher total mortality and eventually in a lower total 
number of COPD patients.  
If 60% of the incidence is in mild COPD and 40% in moderate COPD, more patients in 
the mild and moderate will result in a lower total mortality and a higher total number of 
COPD patients.  
Furthermore, the assumption on a more than exponential decline in lung function had a 
rather large influence on the mortality rate for very severe COPD. This did not however 
result in large effects on total COPD prevalence, mortality or costs. 
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7. Results: projections for the smoking cessation scenarios 
 
In this chapter results are described for the two smoking cessation scenarios, H-MIS and 
IC+Bupr, assuming that these interventions were offered to an additional proportion of 
25% of all smoking COPD patients for a period of either 1 year, 10 years or 25 years.  
As a result of the two smoking cessation scenarios the proportions of smokers among 
the COPD population decreases, while the proportions of ex-smokers increases. 
Because lung function decline and mortality are lower among ex-smokers than among 
smokers, the course of disease improves and mortality decreases. As a result the 
absolute number of COPD patients increases slightly. But the severity distribution of 
COPD shifts toward the less severe stages. This generates a gain in life-years, quality-
adjusted life-years and savings in COPD-related health care costs. Note that restart 
rates are larger than zero, so that in the long run, the proportions of smokers and ex-
smokers return to their base-case values. The outcomes in (quality adjusted) life-years 
and savings will be discussed in section 7.2 after a short description of the impact of the 
smoking cessation scenarios on smoking status, mortality, severity distribution of COPD 
and the total number of COPD patients in 7.1.  
Time horizons of 25 and 50 years are considered, i.e. cumulative costs and effects of the 
1 year, 10 year and 25 year implementation of H-MIS and IC+Bupr are studied over a 
period of 25 years and 50 years.  
 
7.1 Changes in the COPD population 
 
Change in the proportional distribution of smoking  
In 2000 4% of the male COPD patients was never smoker, 50% was smoker and 46% 
was ex-smoker. Among female COPD patients 19% was never smoker, 49% was 
smoker and 32% was ex-smoker.  
In table 7.1 the distribution of COPD patients over smoking classes in 2025 is shown for 
the base-case and the two smoking cessation scenarios, for a 25 year implementation 
period. 
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Table 7.1: Proportion (%) of smokers and ex-smokers among COPD patients in 2025 
  Never smoker Smoker Ex-smoker 
Base-case Men 6 44 50 
 Women 11 50 39 
     
25% of the COPD patients gets 
H-MIS 
Men 
Women 
6 
11 
42 
48 
52 
41 
     
25% of the COPD patients gets 
IC+Bupr 
Men 
Women 
6 
11 
37 
42 
57 
47 
 
For both scenarios the proportion of smokers decreases, while the proportion of ex-
smokers increases. In the base-case scenario the total number of smoking COPD 
patients increases from 152000 in the year 2000 to 231000 in the year 2025. 
Implementation of the H-MIS scenario results in 221000 smoking COPD patients in 
2025, a decrease of 10000 smoking COPD patients compared to base-case. The 
IC+Bupr scenario results in 195000 smoking COPD patients in 2025, which is a 
decrease of 35000 compared to the base-case scenario.  
 
Change in mortality 
Compared to base-case all-cause mortality decreases with 0.3% after implementation of 
H-MIS and 1.2% after implementation of IC+Bupr. In table 7.2 all-cause mortality rates 
per 1000  COPD patients are shown.  
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Table 7.2: All-cause mortality rates in each of the severity stages per 1000 COPD 
patients and mortality in absolute numbers for the year 2025 
All-cause mortality rates Mild Moderate Severe Very 
severe 
Base-case 24.0 37.1 13.2 5.7 
     
25% of the COPD patients gets H-MIS 24.0 37.0 13.1 5.5 
25% of the COPD patients gets IC+Bupr 24.1 36.8 12.8 5.2 
     
Mortality in absolute numbers      
Base-case 11900 18400 6500 2800 
     
25% of the COPD patients gets H-MIS 11900 18300 6500 2700 
25% of the COPD patients gets IC+Bupr 11900 18200 6300 2600 
 
For both the scenarios mortality rates in severe and very severe COPD decrease 
slightly. For IC+Bupr the mortality rate in mild COPD increases little, because of the 
increase in the total number of mild COPD patients.  
 
Change in COPD severity distribution 
After implementation of H-MIS the total number of mild and moderate COPD patients in 
2025 increases with 740 and 270 patients respectively compared to the base-case 
scenario, while the number of patients in severe and very severe COPD decreases with 
370 and 380 patients, respectively. Implementation of IC+Bupr results in an increase of 
mild COPD with 2800 and moderate COPD with 880 patients, while the number of 
patients in severe and very severe COPD decreases both with 1300 patients. In table 
7.3 the proportional change of the total number of patients in each severity stage 
between 2000 and 2025 compared to the base-case scenario is shown for the different 
scenarios. For example, in the IC+Bupr scenario, the total number of female severe 
COPD patients is projected to be 2.0% lower in 2025 than it was in the base-case in 
2025. 
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Table 7.3: Proportional change (%) of the total number of patients in each severity stage 
between 2000 and 2025 compared to base-case 
  Mild Moderate Severe Very severe 
25% of the COPD patients 
gets H-MIS 
Men 
Women 
+0.4 
+0.4 
+0.1 
+0.1 
-0.6 
-0.5 
-1.8 
-1.8 
25% of the COPD patients 
gets IC+Bupr 
Men 
Women 
+1.6 
+1.5 
+0.3 
+0.5 
-2.2 
-2.0 
-6.1 
-6.4 
 
 
Change in total number of COPD patients 
In 2000 the model projects a total number of COPD patients of 305 800, 188 400 men 
and 117 400 women. Total number of COPD patients in 2025 for the two smoking 
cessation scenarios are shown in table 7.4.  
 
Table 7.4  Total number of COPD patients in 2025 
 Men Women Total 
Base-case 269 900 224 400 494 300 
    
25% of the COPD patients gets H-MIS 270 000 224 500 494 500 
25% of the COPD patients gets IC+Bupr 270 400 224 900 495 200 
 
Because complete recovery from COPD after smoking cessation is impossible and ex-
smoking is associated with a lower mortality risk, the total number of COPD patients 
after 25 years is slightly higher for both scenarios: about 250 more COPD patients after 
implementation of H-MIS and about 1000 more COPD patients after implementation of 
IC+Bupr.  
 
7.2 Cost-effectiveness analyses 
 
Table 7.5 shows the total number of additional quitters and total intervention costs in 
2001, when the smoking cessation interventions are implemented for 1 year. Costs per 
extra quitter included only intervention costs, because savings occur later. They were 
700 for H-MIS and 2700 for IC+Bupr. 
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Table 7.5: Number of additional quitters, total intervention costs and costs per quitter 
compared to the base-case scenario after a 1-year implementation of the 
smoking cessation interventions (Euros, year 2000 price level)  
 Additional quitter Intervention costs (*103) Costs per quitter 
H-MIS 1200 800 700 
IC+Bupr 4700 12700 2700 
 
Table 7.6 shows the undiscounted estimates of cumulative costs and effects over a 
period of 25 years and the resulting cost-effectiveness ratios in terms of life-years and 
QALYs gained. For both scenarios it was assumed that the smoking interventions were 
offered each year during a period of either 1, 10 or 25 years.  
 
 
Table 7.6: Number of life-years and QALYs gained, total additional intervention costs, 
total savings and cost-effectiveness: costs per life-year gained and costs per 
QALY gained for the two scenarios, cumulative for the years 2000-2025 
(Euros, year 2000 price level) 
Duration of 
implementa-
tion 
LYs 
gained 
QALYs 
gained 
Intervention 
costs (*106) 
Savings in 
COPD-
related costs 
(*106) 
Costs per 
LY gained 
Costs 
per 
QALY 
gained 
1 year       
H-MIS 200 400 0.8 2.6 # # 
IC+Bupr 900 1800 13 9.9 2900 1500 
       
10 year        
H-MIS 2000 4300 8.4 25 # # 
IC+Bupr 7300 16000 124 93 4200 2000 
       
25 year        
H-MIS 2800 7100 24 45 # # 
IC+Bupr 10400 26000 346 160 17900 7200 
# H-MIS dominates the base-case, due to net cost savings and higher effects 
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Regardless of the duration of implementation, the H-MIS scenario saves costs. When 
the H-MIS is offered each year to an additional 25% of all smoking COPD patients during 
a period of 25 year, the cumulative net saving is 20.4 million Euros. The IC+Bupr 
scenario has higher costs than savings. The costs per life-year gained are estimated to 
be 17900 Euros and the costs per QALY gained are estimated to be 7200 Euros, when 
choosing a 25 year implementation period. When opting for a 1 year implementation 
costs per life-year gained and cost per QALY gained are 2900 Euros and 1500 Euros 
respectively. 
Table 7.7 shows the same results as in table 7.6, but now 4% discounting is applied to 
both costs and effects.  
 
Table 7.7: Number of life-years and QALYs gained, total additional intervention costs, 
total savings and cost-effectiveness: costs per life-year gained and costs per 
QALY gained for the two scenarios, cumulative for the years 2000-2025, 
discounted at 4% for both costs and effects (Euros, year 2000 price level) 
Duration of 
implementa-
tion 
LYs 
gained 
QALYs 
gained 
Intervention 
costs (*106) 
Savings in 
COPD-
related costs 
(*106) 
Costs per 
LY 
gained 
Costs per 
QALY 
gained 
1 year        
H-MIS 100 300 0.8 1.8 # # 
IC+Bupr 500 1200 12.6 6.9 10600 4900 
       
10 year        
H-MIS 1100 2500 7.1 15.2 # # 
IC+Bupr 4000 9400 104.6 56.6 12000 5100 
       
25 year        
H-MIS 1400 3800 15.3 24.5 # # 
IC+Bupr 5400 14100 219.1 88.0 24500 9300 
# H-MIS dominates the base-case, due to net cost savings and higher effects 
 
Regardless of the implementation period, H-MIS was still a dominant strategy compared 
to current practice, because effects were higher and costs savings were higher than 
intervention costs.  When opting for a 25 year implementation period at 4% discounting, 
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1400 life-years are gained and 24.5 million Euros of COPD-related costs are saved. 
Interventions costs over the 25-year period are 15.3 million Euros, resulting in a net 
saving of 9.2 million Euros.  
IC+Bupr is more effective. Over the 25 year period 5400 life years are saved. But the 
intervention costs are much higher and not fully offset by extra savings. Dividing the 
additional costs by the gain in health, costs per life-year gained and per QALY gained 
were estimated to be about 24500 Euros and 9300 Euros respectively. These ratios are 
considerably reduced when IC+Bupr is offered to an additional 25% of smoking COPD 
patients for only 1 year. Of course, total QALYs and life-years gained are also much 
lower. 
 
Effects and costs over time 
Figure 7.1 shows the undiscounted number of life-years gained for H-MIS and IC+Bupr 
with 10 years of implementation, compared to the base-case scenario, in each of the 
years 2000 to 2050. Gain in life-years reached a peak about 20 years after start of the 
implementation. The undiscounted cumulative gain in life-years was 3300 for H-MIS and 
12300 for IC+Bupr.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1: Number of QALYs gained in each individual year for the two smoking 
cessation scenarios, compared to base-case, over the years 2000-2050, 
0% discounting, 10 year implementation period 
 
Figure 7.2 shows the undiscounted cumulative savings in COPD-related costs of care 
and the additional intervention costs for the scenario in which H-MIS is offered for 1 year, 
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compared to base-case. The break-even point is reached after 6 years, when cumulative 
savings become equal to the intervention costs. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2: Cumulative interventions costs and savings in COPD-related costs for 1 year 
implementation of H-MIS, compared to base-case, over the years 2000-
2050, 0% discounting. 
 
Just like the H-MIS cumulative savings of IC+Bupr increase over time, but they never 
exceed the intervention costs (figure 7.3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3: Cumulative interventions costs and savings in COPD-related costs for 1 year 
implementation of IC+Bupr, compared to base-case, over the years 2000-
2050, 0% discounting 
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In figure 7.4 annual differences in total COPD-related costs per severity stage are shown 
for IC+Bupr compared to base case after a 25 year period of implementation. 
 
 
 
 
 
 
 
 
Figure 7.4: Absolute difference in total costs of care per severity class for IC+BU 
scenario compared to base-case, 0% discounting, 25 year implementation 
 
Implementation of IC+Bupr results in lower total costs compared to base-case, which is 
mostly due to the high savings in the very severe COPD stage.  
 
7.3 Sensitivity analyses for cost-effectiveness 
From the sensitivity analyses for the base-case scenario in chapter 6 we concluded that 
the sensitivity analyses about the severity distribution of incidence influence the results 
the most. Therefore we chose these two sensitivity analyses for the sensitivity analyses 
of the cost-effectiveness. Table 7.8 shows results for the cost-effectiveness when the 
severity distribution of incidence is assumed to be equal to the distribution of the 
prevalence and when the severity distribution of incidence is 60% in mild and 40% in 
moderate. The interventions were implemented for 25 years.  
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Table 7.8: Number of life-years and QALYs gained, total additional intervention costs, 
total savings and cost-effectiveness: costs per life-year gained and costs per 
QALY gained for the two scenarios, for a 25 year implementation , 
cumulative for the years 2000-2025, with different assumptions for the 
severity distribution of incidence, discounted at 4% for both costs and effects 
(Euros, year 2000 price level)  
Intervention LYs 
gained 
QALYs 
gained 
Interventio
n costs 
(*106) 
Savings in 
COPD-
related 
costs 
(*106) 
Costs per 
LY gained 
Costs per 
QALY 
gained 
Base-case       
H-MIS 1400 3800 15 25 # # 
IC+Bupr 5400 14100 219 88 24500 9300 
       
Severity distribution of incidence as prevalence    
H-MIS 1600 4300 15 30 # # 
IC+Bupr 5800 15600 216 106 18900 7000 
       
Severity distribution of incidence: 60% in mild, 40% in moderate   
H-MIS 1300 3300 16 19 # # 
IC+Bupr 4800 12000 222 68 32300 12800 
 
A severity distribution of incidence resembling the distribution of prevalence gives a shift 
to the severe and very severe COPD compared to base-case. Because mortality is 
higher in the more severe stages, implementation of smoking cessation interventions on 
more severe patients will gain more life-years.  Costs per life-year and costs per QALY 
are lower than for the base-case.   
If the severity distribution of incidence is 60% in mild and 40% in moderate a shift to mild 
and moderate COPD occurs. Because mortality is lower in these stages, less life-years 
can be gained, which results in higher costs per life-year and costs per QALY than for 
the base-case. 
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Time horizon 
Table 7.9 shows the impact of the time horizon on life-years, QALYS and total costs as 
well as the cost-effectiveness ratios.  The same results as in table 7.7 are shown, but 
now for a time horizon of 50 years. 
 
Table 7.9: Number of life-years and QALYs gained, total additional intervention costs, 
total savings and cost-effectiveness: costs per life-year gained and costs per 
QALY gained for the two scenarios, cumulative for the years 2000-2050, 
discounted at 4% for both costs and effects (Euros, year 2000 price level) 
Duration of 
implementa-
tion 
LYs 
gained 
QALYs 
gained 
Intervention 
costs (*106) 
Savings in 
COPD-
related costs 
(*106) 
Costs per 
LY 
gained 
Costs per 
QALY 
gained 
1 year        
H-MIS 100 300 0.8 1.8 # # 
IC+Bupr 600 1300 13 7.0 8800 4400 
       
10 year        
H-MIS 1400 2900 7.1 16 # # 
IC+Bupr 5400 10500 105 61 8100 4000 
# H-MIS dominates the base-case, due to net cost savings and higher effects 
 
For both time horizons of 25 and 50 year H-MIS was a cost-saving intervention. For 
IC+Bupr cost-effectiveness ratios become more favourable for a longer time period.  
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8. Discussion and conclusion 
 
In the present study we have developed a COPD model that includes the progression of 
COPD over time. The model can be characterised as a dynamic, population-based 
model, that represents the Dutch setting. It was used to simulate the incidence, 
prevalence, mortality and costs of COPD by severity stage over the years 2000 to 2025. 
It is important to stress that the current model is populated with data on physician-
diagnosed COPD in the Netherlands. In contrast to population studies, these data do not 
cover patients with undiagnosed COPD. 
 
In the base-case scenario, the prevalence rate of mild COPD increases from 5.1 to 10.7 
per 1000 inhabitants. The prevalence rate for moderate COPD increases from 10.7 to 
14.1. For severe COPD the rate increase from 3.0 to 3.9 and for very severe COPD the 
rates increase from 0.5 to 1.3. In absolute numbers the increase between 2000 and 
2025 was highest in mild COPD, but the largest relative increase was seen in the 
prevalence rate of very severe COPD. As a result of the increase in COPD prevalence 
and aging of the COPD population, all-cause mortality rates per 1000 inhabitants 
increase in all severity stages. In 2000, total COPD-related costs were estimated to be 
279.7 million Euros, 8% caused by care for patients with mild COPD, 37%, 35% and 
19% caused by care for patients with moderate, severe and very severe COPD, 
respectively. Between 2000 and 2025 total projected COPD-related costs increased from 
22.6 to 51.2 million Euros for mild COPD, from 104 to 148 million Euros for moderate 
COPD, from 99.0 to 140 million Euros for severe COPD, and from 54.5 to 156 million 
Euros for very severe COPD.   
 
The reason to develop this model was to be able to evaluate the cost-effectiveness of 
COPD interventions in the Netherlands at a population level. To illustrate the use of this 
model for this purpose we have estimated the cost-effectiveness of two smoking 
cessation scenarios for COPD compared to current practice. In the first scenario we 
assume that an additional proportion of 25% of all smoking COPD patients receive the 
H-MIS. In the second scenario we assume that an additional proportion of 25% of all 
smoking COPD patients receive IC+Bupr. We reported cumulative results over the 
period 2000 to 2025 when implementing these smoking cessation scenarios for a period 
of either 1 year, 10 years or 25 years. Irrespective of the duration of implementation, the 
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H-MIS generates net savings, which indicates that the intervention costs of the H-MIS 
are offset by the savings in COPD-related health care costs. When implementing the H-
MIS scenario for a period of 10 years, about 1100 life years are gained. IC+Bupr is more 
effective. When implementing this scenario for a period of 10 years, about 4000 life 
years are gained and 56.6 million of COPD-related costs are saved. However, these 
savings do not outweigh the interventions costs. The costs per life-year gained of 
implementing IC+Bupr for 10 years are estimated to be about 12000 Euros.  
 
We have recently estimated the cost-effectiveness of smoking cessation interventions 
directed at the smokers among the general population in the Netherlands (Feenstra et 
al., 2003). These calculations included the life years gained and costs saved as a result 
of the primary prevention of 11 smoking related diseases. Because of the broader 
scope, the cost effectiveness ratio of 4700 per life year gained for 1 year implementation 
of IC+Bupr in that project was better than the ratio in the current project. However, for a 
fair comparison, that cost-effectiveness ratio should be recalculated, and only include the 
life years gained and savings from the primary prevention of COPD. In that case, the 
cost-effectiveness of primary prevention of COPD by offering IC+Bupr to 25% of all 
smokers in the general population is 34 000 Euros per life year gained, compared to 11 
000 Euros per life year gained for offering IC+Bupr for 1 year to 25% of all existing 
COPD patients (costs and effects discounted at 4%). This shows that smoking cessation 
interventions directed at known COPD patients are cost-effective. The H-MIS generates 
net savings and the costs per life year gained of IC+Bupr are below the 20.000 Euros, 
the often cited limit for the cost-effectiveness of preventive interventions (Casparie et al., 
1998). 
 
These estimates of the cost-effectiveness of smoking cessation interventions for COPD 
patients are probably conservative. We only included savings that result from a slower 
progression through the COPD severity stages and no savings that results from a 
reduction in the number or severity of exacerbations or disease episodes. We also take 
into account that ex-smokers can restart smoking. 
 
Obviously, dynamic disease modelling of COPD as reported here requires a fair degree 
of simplification. For example, we had to assume that the progression of COPD depends 
primarily on decline in FEV1% predicted, which, in turn, depends on age, gender, 
smoking class and absolute level of FEV1% predicted. In the real world many different 
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factors, such as the smoking history, the susceptibility to smoking, the number and 
severity of COPD exacerbations, co morbidity and nutritional status drive the progression 
of COPD. However, there are not enough data yet on the association between these 
factors and disease progression to include them into this model. 
  
Because of the limited availability of suitable epidemiological data, making assumptions 
is unavoidable. For the starting year we had to assume the same distribution of COPD 
severity for each subgroup of COPD patients defined by age, gender and smoking 
status. Although the absolute number of severe and very severe COPD patients is 
highest among smokers and increases with age, the number of severe and very severe 
patients as a proportion of the total number of COPD patients is the same in each 
subgroup. We had to make this assumption for the severity distribution of COPD 
prevalence in the start year 2000 and the severity distribution of COPD incidence. This 
may result in underestimates for our base case projections of the difference in severity 
distribution between smokers and ex smokers. 
 
There were no data from which we could estimate the severity distribution of COPD 
incidence. For a stable population with regard to age, gender and smoking status, and 
given the prevalence, decline in lung function and mortality in the year 2000, we 
estimated the severity distribution of the incidence in such a way that the distribution of 
FEV1% predicted for the entire COPD population did not change between 2000 and 
2001. That same estimated severity distribution of the incidence was then applied in 
each of the future years. Thus the model projections reflect the effects of ageing and 
projected changes in the distribution of smoking status on COPD prevalence and 
severity. In the sensitivity analyses we have shown that our results were most sensitive 
to changes in the assumptions about the severity distribution of the incidence of COPD.  
 
Estimates of the decline in FEV1% predicted among smokers and ex-smokers were 
obtained from the 5-year follow-up data of the Lung Health Study. These data were also 
used to estimate the increase in FEV1% predicted after smoking cessation. Although the 
Lung Health Study is the best and largest study on the effects of smoking and smoking 
cessation on lung function in COPD, it has limitations for our purpose. The study 
primarily recruited patients with mild or moderate airflow obstruction between 35 and 60 
years of age and followed them for 5 years. Decline in lung function (and increase after 
smoking cessation) for patients outside the observed age and lung function range had to 
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be based on extrapolation of the random effect model. The decline in lung function 
among never smokers was assumed to equal the decline among ex-smokers. We 
thought this would be more realistic than assuming that the decline equals the decline 
among never smokers in the general population, because, after all, these patients do 
have COPD. The alternative assumption was tested in a sensitivity analysis. Since the 
group of never smokers is a minority of COPD patients, changing their lung function 
decline did not change total results much.  
 
We have estimated the total costs of COPD in 2000 in the Netherlands. This estimate 
was based on many different sources of routinely registered data and included all 
important cost drivers. However, there were no Dutch observational studies that reported 
the costs by COPD severity stage. Although we had some cost-by-severity data from 
Dutch randomised clinical trials we preferred to apply data from a Swedish observational 
study that reported costs by COPD severity to the Dutch cost estimates, because the 
trial data would be less representative for the total population of COPD patients. 
 
All assumptions and choices about crucial input data were discussed with the expert 
panel and sensitivity analyses were performed on those assumptions and data that gave 
most rise to discussion by the experts. These sensitivity analyses showed that the 
results were quite robust to changes that we made in the severity distribution of COPD 
prevalence by age, the decline in FEV1% predicted, the one-time increase in FEV1% 
predicted after smoking cessation and the association between lung function and 
mortality.     
 
In conclusion, dynamic disease modelling can be of great help in representing and 
identifying trends in the future burden and costs of COPD and in assessing the impact of 
smoking cessation interventions offered to patients already diagnosed with COPD. In the 
future the model can be used to extrapolate clinical trial results to the Dutch COPD 
population in a transparent and consistent way. The current model may be seen as a 
basis for extension, enabling new data to be included if they become available. For 
instance, it would be very interesting to be able to add exacerbation frequencies and 
costs of exacerbations to each severity stage. This would allow us to estimate the cost-
effectiveness of treatments that primarily reduce the frequency and severity of 
exacerbations and have less impact on disease progression. 
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Appendix A: Tables of chapter 2, update of the existing COPD 
model 
 
 
Table A1: Dutch population by gender and 5-year age classes in 2000. 
 Absolute numbers Total mortality among COPD 
patients (/100000/year) 
 Men Women Men Women 
0-4 503570 479921 0 0 
5-9 512470 489200 0 0 
10-14 490343 470039 0 0 
15-19 474911 452554 0 0.22 
20-24 486242 472644 0 0.21 
25-29 594775 581496 0.54 0.18 
30-34 671528 642876 0.45 0.15 
35-39 669674 645269 0.3 0.46 
40-44 614400 599941 1.74 0.81 
45-49 575390 559041 4.12 2.99 
50-54 582697 562629 4.57 5.94 
55-59 435692 423754 13.07 15.88 
60-64 358118 365334 41.37 29.22 
65-69 305154 339326 106.1 50.05 
70-74 242386 307985 232.32 99.67 
75-79 180613 276639 532.22 167.26 
80-84 93057 181569 843.27 214.06 
85+ 58297 167416 1472.86 453.94 
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Table A2: Age- and gender-specific prevalence, incidence and mortality rates (number 
per 1000) for the start year 2000 
 Prevalence Incidence COPD excess mortality 
per 1000 COPD 
patients 
 Men Women Men Women Men Women 
45-49 15.9 13.9 1.6 1.9 29.5 29.5 
50-54 25.0 19.7 2.8 2.7 30.0 30.0 
55-59 40.5 25.9 4.8 2.5 29.5 29.5 
60-64 64.3 33.8 7.1 3.3 30.0 30.0 
65-69 104.4 48.9 11.6 4.8 33.0 33.0 
70-74 144.5 63.1 14.7 5.7 38.0 38.0 
75-79 167.4 65.4 17.0 4.6 43.0 43.0 
80-84 178.5 59.4 13.1 3.8 44.5 44.5 
85+ 175.7 61.6 1.9 6.0 42.5 42.5 
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 Table A3: Proportions of non-smokers, smokers and ex-smokers  
 Proportions in 1998 
 Men Women 
 Never 
smoker 
Smoker Ex-smoker Never 
smoker 
Smoker Ex-smoker 
0-4 1 0 0 1 0 0 
5-9 1 0 0 1 0 0 
10-14 0.90 0.1 0 0.90 0.10 0 
15-19 0.73 0.26 0.01 0.74 0.24 0.02 
20-24 0.57 0.39 0.04 0.60 0.34 0.06 
25-29 0.49 0.43 0.08 0.56 0.33 0.11 
30-34 0.48 0.41 0.11 0.48 0.36 0.16 
35-39 0.43 0.41 0.16 0.42 0.39 0.19 
40-44 0.36 0.44 0.20 0.39 0.41 0.20 
45-49 0.36 0.41 0.23 0.45 0.36 0.19 
50-54 0.34 0.39 0.27 0.51 0.31 0.18 
55-59 0.36 0.36 0.28 0.57 0.26 0.17 
60-64 0.30 0.34 0.36 0.57 0.24 0.19 
65-69 0.28 0.31 0.41 0.64 0.17 0.19 
70-74 0.28 0.31 0.41 0.64 0.17 0.19 
75-79 0.32 0.28 0.40 0.69 0.14 0.17 
80-84 0.34 0.26 0.40 0.76 0.10 0.14 
85+ 0.36 0.24 0.40 0.84 0.06 0.10 
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Table A4: Age- and gender-specific start, cessation and restart probabilities for smoking  
 Proportions changing smoking class 
 Men Women 
 Start Cessation Restart Start Cessation Restart 
0-4 0 0 0 0 0 0 
5-9 0 0 0 0 0 0 
10-14 0.028 0.007 0 0.037 0.007 0 
15-19 0.046 0.015 0 0.039 0.015 0 
20-24 0.042 0.018 0.031 0.016 0.027 0.014 
25-29 0.006 0.025 0.097 0 0.033 0.053 
30-34 0 0.031 0.129 0 0.038 0.097 
35-39 0 0.036 0.114 0 0.040 0.098 
40-44 0 0.039 0.099 0 0.041 0.114 
45-49 0 0.042 0.085 0 0.042 0.099 
50-54 0 0.045 0.070 0 0.043 0.084 
55-59 0 0.048 0.055 0 0.043 0.069 
60-64 0 0.049 0.040 0 0.044 0.055 
65-69 0 0.049 0.025 0 0.046 0.040 
70-74 0 0.047 0.010 0 0.051 0.025 
75-79 0 0.047 0 0 0.051 0.010 
80-84 0 0.047 0 0 0.051 0 
85+ 0 0.047 0 0 0.051 0 
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 Table A5: Relative risks of smokers and ex-smokers to get COPD 
 Relative Risks for COPD incidence 
 Men Women 
Age Smoker Ex-smoker Smoker Ex-smoker 
45-49 13.6 11.2 12.3 8.3 
50-54 13.6 11.2 12.3 8.3 
55-59 13.6 11.2 12.3 8.3 
60-64 13.6 11.2 12.3 8.3 
65-69 13.6 11.2 12.3 8.3 
70-74 9.8 7.4 8.9 5.9 
75-79 9.8 7.4 8.9 5.9 
80-84 9.8 7.4 8.9 5.9 
85+ 9.8 7.4 8.9 5.9 
The RR for a non-smoker is 1. 
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Appendix B: Tables of chapter 3, description of the new COPD 
model  
  
Table B1: NMP-data: General characteristics, co morbidities and medication  
 With spirometry (n=307) Without spirometry 
(n=223) 
% Female 39.1 38.6 
Age 65.6 65.9 
% with angina pectoris 10.7 13.5 
% with myocardial infarct  6.8 7.2 
% with heart failure 7.2 9.0 
% with hypertension 14.3 14.8 
% with CVA 3.9 4.9 
% with diabetes 7.6 9.4 
   
“COPD-medication” in 
2000 (mean 
prescriptions/patient): 
7.2 7.7 
Corticosteroids (H02) 0.4 0.6 
Antibacterials (J01)  0.8 0.8 
Anti-asthmatics (R03) 5.7 5.7 
Cough and cold 
preparations (R05) 
0.3 0.6 
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Table B2: EMGO-data: Characteristics of the study population with a physician 
diagnosis of COPD  
Physician 
diagnosis: 
COPD 
(n=138) 
COPD + 
asthma 
(n=153) 
Unknown 
whether they 
have asthma 
or COPD 
(n=410) 
Total 
(n=701) 
% female  44 54 54 52 
63 58 49 54 
Weight (kg) 77 77 79 78 
Height (m) 1.70 1.70 1.72 1.71 
FEV1 (l) 2.06 2.42 2.95 2.66 
FEV1% pred  72 83 92 86 
Reversibility(%) 5 7 6 6 
Smoking status 
(%) 
    
Never smoker 12 26 4 10 
Current smoker 45 37 8 22 
Ex-smoker 40 31 10 21 
Missing 4 5 78 47 
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Table B3: Baseline characteristics of the LHS study population 
N=5887 Mean 
Gender (% female) 37 
Age (year) 48,5 
Education (years) 13,6 
BMI 25,6 
  
Smoking:  
Cigarettes/day 26,1 
Age started smoking 17,5 
Packyears 40,5 
  
Lung function (post-BD):  
FEV1  (L) 2,75 
FEV1 % pred 78,3 
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Table B4: Regression coefficients of the random effect model 
 β-Coefficient p-value 
   
Intercept -20.9546 0.26 
Year 0.2394 0.33 
Smoking cessation 14.3188 <0.0001 
Gender 7.3174 0.10 
Age 1.1132 0.13 
Baseline FEV1% predicted 1.3646 <0.0001 
Year*smoking cessation 0.4556 <0.0001 
Year*gender -0.1562 <0.0001 
Year*age -0.03144 <0.0001 
Year*baseline FEV1% predicted 0.006027 <0.01 
Smoking cessation*gender 1.7297 <0.0001 
Smoking cessation*baseline FEV1% 
predicted 
-0.1242 <0.0001 
Gender*age -0.4038 <0.05 
Gender*baseline FEV1% predicted 0.02723 <0.05 
Age*baseline FEV1% predicted -0.01818 <0.05 
Age2 -0.01213 0.10 
Age2*smoking cessation -0.00086 <0.0001 
Age2*gender 0.004299 <0.05 
Age2*baseline FEV1% predicted 0.000197 <0.05 
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Table B5a: Proportion transitioning to another severity stage associated with 
yearly decline in 2000 
From: Never-
smokers 
Smokers Ex-smokers 
Mild to moderate1 1.8% 2.5% 2.1% 
Moderate1 to 
moderate2 
7.1% 9.4% 8.2% 
Moderate2 to severe 5.1% 6.4% 5.9% 
Severe to very severe 2.6% 3.1% 3.0% 
 
Table B5b: Proportion transitioning to another severity stage associated with the 
increase after smoking cessation: 
From: Never-
smokers 
Smokers Ex-smokers 
Moderate1 to mild - - 1.3% 
Moderate2 to 
moderate1 
- - 1.7% 
Severe to moderate2 - - 1.7% 
Very severe to severe - - 1.8% 
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Table B6: Unit costs in 2000 used to calculate total costs for COPD 
Unit Cost (Euros) 
GP-visit 17 
Outpatient visit 50 
Home care (hour) 8.70 
  
Daycare treatment 177 
Inpatient hospital day 271 
  
Influenza vaccination 15. 
Oxygen (day) 4.20 
  
Lung transplantation 186 000 
 
 
A Health Policy Model for COPD: Effects of Smoking Cessation  81
Tabel B7: Total number of admissions for COPD in 2000 (LMR, 2000) 
 Day-care treatment Clinical admission 
 Men Women Men Women 
45-49 year 39 51 252 315 
50-54 year 34 61 388 558 
55-59 year 46 73 638 768 
60-64 year 74 72 1068 862 
65-69 year 122 58 1807 1347 
70-74 year 130 47 2448 1410 
75-79 year 78 27 2366 1238 
80-84 year 12 14 1323 815 
85+ 7 6 606 588 
Total 542 409 10896 7901 
 
 
 
Tabel B8: Total number of inpatient days for COPD in 2000 (LMR, 2000) 
 Day-care treatment Clinical admission 
 Men Women Men Women 
45-49 year 39 51 3639 4412 
50-54 year 34 61 4943 8450 
55-59 year 46 73 8803 10658 
60-64 year 74 72 15092 12069 
65-69 year 124 58 26030 20112 
70-74 year 134 48 35468 22753 
75-79 year 78 27 36049 18428 
80-84 year 12 15 19685 12537 
85+ 7 6 9583 8952 
Total 548 411 159292 118371 
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Table B9: Total costs for nursing and residential care facilities in million Euros (Polder et 
al., 2002) 
Age Men Women 
45 - 64 year 1,1 0,9 
65 - 74 year 3,4 2,4 
75 - 84 year 7,4 6,0 
85+ 5,7 7,5 
Totaal 17,6 16,8 
 
 
 
Table B10: Total costs in million Euros for medication (SFK, 2000) 
 Men Women 
45 – 54 year 4.98 6.43 
55 – 64 year 6.75 6.40 
65 – 69 year 4.91 3.85 
70 – 74 year 5.84 4.05 
75+  9.64 7.56 
Total 32.1 28.3 
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Table B11: Costs/patient in Euros divided by age, gender and disease severity 
 Mild patient Moderate patient Severe patient Very severe patient 
Men     
45-49 year 210 460 1600 5200 
50-54 year 210 450 1500 5100 
55-59 year 210 450 1500 5100 
60-64 year 220 480 1600 5400 
65-69 year 240 530 1800 5900 
70-74 year 260 570 1900 6400 
75-79 year 310 680 2300 7600 
80-84 year 310 670 2300 7500 
85+ 410 900 3100 10000 
Total 260 570 1900 6400 
     
Women     
45-49 year 270 590 2000 6600 
50-54 year 280 620 2100 7000 
55-59 year 280 610 2100 6900 
60-64 year 280 620 2100 6900 
65-69 year 300 660 2300 7400 
70-74 year 290 640 2200 7100 
75-79 year 320 690 2400 7800 
80-84 year 330 720 2500 8000 
85+ 460 1000 3500 11000 
Total 310 680 2300 7600 
 
Formula to calculate cost/patient for the different severity stages 
Total costs (a, g)=  costs/patient for mild COPD * number of mild patients (a,g) +  
2.22 * costs/patient for mild COPD * number of moderate patients (a,g) + 
7.51 * costs/patient for mild COPD * number of severe patients (a,g) + 
24.67 * costs/patient for mild COPD * number of very severe patients 
(a,g) 
a=age, g=gender 
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Appendix C: Mathematical description of the new COPD model 
 
This appendix contains a formal, mathematical description of the new COPD model, in 
addition to the verbal description in section 3. The formulas given below summarize the 
Mathematica code that forms the model used in the calculations. For further details, 
please contact the authors.  
To simplify notation, specific subscripts to specify e.g. age, time, or gender will be left out 
in the remainder whenever this does not cause confusion. A formal mathematical 
description of the original RIVM Chronic Disease Model (CDM) can be found in 
Hoogenveen, de Hollander and van Genugten (Hoogenveen et al., 1998). A shorter, 
basic description was published in Feenstra et al (Feenstra et al., 2001). 
 
Like the CDM underlying this COPD model, the new COPD model is a dynamic 
population model, and implemented as a set of difference equations. These equations 
describe the development of the state variables over time, as a result of transitions from 
one state to the other. For instance, the number of current smokers with mild COPD in 
year t+1 is defined by the number of current smokers with mild COPD in year t, adding 
new mild COPD incidence among smokers, adding new as well as restarted ex-smokers 
among mild COPD patients, subtracting smoking cessation in mild COPD patients, 
subtracting decrease in health status to moderate COPD and correcting for mortality. 
The two most important state variables in the COPD model are: 1) population numbers 
per COPD severity stage (this includes not having COPD as a special stage), per 
smoking class, per age class, and gender, and 2) coefficients characterizing the 
distribution of FEV1%pred within each COPD severity stage per smoking class. The 
latter variable has to be interpreted as the mean distribution over both genders and all 
ages. Basically the model describes how these variables evolve over time and how they 
are related. 
 
This appendix follows the computational order in the model. First all input parameters 
are defined or read from data files and some help variables are computed. Then, the 
values of the model variables for the start year are computed or read. Second, for each 
year in the simulation, three calculation steps are set. The 1st step is the calculation of 
the transition numbers between the smoking classes and COPD severity stages. The 
smoking class transition rates are model input. The COPD severity class transition rates 
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are calculated based on lung function decrease and increase estimated on the LHS data 
and the distribution of FEV1%pred in each COPD stage. The 2nd step is the calculation 
of new COPD and smoking prevalence numbers using these transition rates. The 3rd 
step is the calculation of the new FEV1% pred distributions in each COPD stage using 
lung function decrease and increase. Finally the prevalence rates of other smoking 
related diseases are computed following the general CDM disease model equations. 
The main COPD model equations are given below and shortly explained. Tables C1 to 
C3 list the symbols used. 
 
Table C1: Definition of indexsymbols used in model formulas  
Symbol Range Definition  
ri  1,2,3 1=never smokers, 2=current smokers, 3=former 
smokers 
j 1,2 Direction of transitions, 1=forward, 2=backward 
di 1,2,3,4,5,6 COPD severity stages, 1=no COPD, 2=very 
severe, 3=severe, 4=moderate1, 5=moderate2, 
6=mild COPD 
g 1,2 Gender, 1=men, 2=women 
a 1,2,…18, or 
1,2,..86 
Age, either  in five year age classes (1=0-4, 2=5-
9 etc, 18=85 and over) or in one year classes 
(1=0, 2=1 etc, 85=84, 86=85 and over) 
n 1,2,…nstap Time runs from t0 to nstap, the user defined value 
of the last year. 
c 1,2 Index over severity distribution coefficients,  
1= slope, 2= intercept 
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Table C2: Definition of input parameters used in model formulas  
Symbol Value Definition  
RRsmokCOPD(ri,g,a) See table 1.5 Relative risk of smoking class for COPD 
incidence 
N0(g,a)  
 
See table A1 Initial total population numbers  
propprevCOPD(di) See table C7  Initial distribution of COPD prevalence over 
severity stages. 
propinc COPD(di) See table C7 Distribution of COPD incidence over severity 
stages 
distFEV0(di,c) See table C4 Initial set of coefficients characterizing the 
distribution of FEV1%pred within each COPD 
severity stage.  
distFEVinc(di,c) See table C4 Initial set of coefficients characterizing the 
distribution of FEV1%pred within each COPD 
severity stage for COPD incidence. 
incCOPD(g,a) See table  A2 COPD incidence rates, as numbers per 1000 in 
the general population 
morttot(g,a) See table A1 Total mortality rates in the population in start year 
prevCOPD0(g,a) See table A2  COPD prevalence fractions, as a percentage of 
the total population, at baseline. 
excessmortCOPD(g,a) See table A2 Baseline COPD excess mortality rates 
transsmok(j,ri,g,a) See  table A4 Smoking class transition rates  
Prevsmok0(ri,g,a) See table A3 Smoking prevalence fractions in total population at baseline 
RRFEVtot 1.20 
(See section 3.4) 
Relative risk of FEV1%pred value for excess mortality of 
COPD 
RMoth(g,ri,a) See table C5 Multiplier value for non-COPD mortality, i.e. the smoking class 
specific risk of mortality for other causes relative to the 
population risk value. RM (g,2,a) divided by RM (g,1,a) is the 
relative risk of smokers for non-COPD mortality compared to 
never smokers and idem for ex smokers: RM (g,3,a) divided by 
RM (g,1,a) 
mFEV0(di) See table C6 Values for mean FEV1%pred in each COPD severity stage in 
start year. 
FEVlength(di), 
 
See table C6 Length of FEV1 severity stages, computed as upper boundary 
of severity stage minus lower boundary, e.g. for very severe, 30-
0=30. 
FEVbord(di) See table C6 Value of lower limit of FEV1 severity stages 
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Table C3: Definition of model variables  
Symbol Definition  
N(ri,di,g,a) t Population numbers 
distFEV(ri,di,c) t Coefficients of FEV1%pred distribution with each smoking and severity 
stage at start of year, normalized i.e. with cumulative distribution value 1 
distFEVp(ri,di,c) t Idem scaled with true population numbers 
distFEVp1(ri,di,c)t, 
distFEVp2(ri,di,c) t 
Idem, helpvariables to denote temporary values for distFEVp 
f(j,ri,di,g,a) t Change in FEV1%pred over 1 year found from estimated random effects 
model (j=1: decrease, j=2, increase after smoking cessation), specific for 
age and gender 
Mf(j,ri,di) t Mean change in FEV1%pred, weighted average over age and gender  
transCOPD(j,ri,di) t COPD stage transition rates 
mortoth(g,a)  Mortality rate for non modelled causes 
baseincCOPD(g,a) Incidence rate for a non smoker, (without COPD) 
prevsmok0(ri|di,g,a) Smoking prevalence fractions in a given COPD severity stage at t=0 
embaseCOPD(g,a) COPD excess mortality rate for stage mild COPD 
mFEV(ri,di) t Mean FEV1%pred in each COPD severity and smoking class 
 
 
Table C4: Initial set of coefficients characterizing the distribution of FEV1%pred within 
each COPD severity stage. 
Severity stage Intercept 
prevalence 
Slope 
prevalence 
Intercept 
incidenc
Slope 
Incidence 
Mild 0.0166137 -0.000526855 0.0258372 -0.000847084 
Moderate1 0.0211958 -0.000381843 0.0228356 0.000250135 
Moderate2 0.013254 0.00044121 0.00500505 0.000990587 
Severe 0.00241387 0.000542006 -0.00024786 0.000262645 
Very severe 0.0000405213 0.000118668 0 0 
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Table C5: Values for RRoth(g,ri,a)= RMoth(g,ri,a)/RMoth(g,1,a),  
average over men and women.  
 
RMoth(g,ri,a)/RMoth(g,1,a). 
 
 
Age class 
Current  smokers Former  smokers 
0-29 1 1 
30-49 1.9 1 
50-59 1.8 1.1 
60-69 2.0 1.2 
70-79 1.7 1.2 
80+ 1.4 1.2 
 
 
Table C6: Values for mFEV in start year, FEVbord, FEVlength. 
Severity stage MFEV0 FEVbord FEVlength 
Mild 90 80 30 
Moderate1 74 68 12 
Moderate2 60 50 18 
Severe 42 30 20 
Very severe 23 0 20 
 
 
Table C7: Initial distribution of inc and prev over each COPD severity stage. 
Severity stage prevalence incidence 
Mild 0.27 0.40 
Moderate1 0.23 0.30 
Moderate2 0.32 0.25 
Severe 0.15 0.045 
Very severe 0.026 0.0015 
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Initialisation 
 
 
Distribute COPD prevalence over smoking and severity stages. 
 
The baseline values for smoking and severity stage specific prevalence fractions are 
found as follows:  
 
prevsmok0(1|di,g,a) = RRsmokCOPD(1,g,a) prevsmok0(1,g,a) / ( Σri RRsmokCOPD(ri,g,a) prevsmok0(ri,g,a) ),  
prevsmok0(2|di,g,a) = RRsmokCOPD(2,g,a) prevsmok0(2,g,a) / ( Σri RRsmokCOPD(ri,g,a) prevsmok0(ri,g,a) ),  
prevsmok0(3|di,g,a) = RRsmokCOPD(3,g,a) prevsmok0(3,g,a) / ( Σri RRsmokCOPD(ri,g,a) prevsmok0(ri,g,a) ),  
all three for di=2,..6.  
 
And for di=1: 
prevsmok0(ri|1,g,a) =( prevsmok0(ri,g,a) - prevCOPD0(g,a) prevsmok0(ri|di,g,a) )) /(1- prevCOPD0(g,a)), 
ri=1,..3 
 
The relative risk values used for calculating smoking class specific COPD incidence 
numbers were assumed to approximate the relative risk of smoking class for COPD 
prevalence for the start year. Furthermore, the prevsmok0(ri|di,g,a) are assumed equal for 
all di>1, for the start year. 
 
The population numbers in each severity and smoking class for the start year are then 
calculated as follows:  
 
N(ri,di,g,a)t=0 = N0(g,a) prevCOPD0(g,a) prevsmok0(ri|di,g,a) propprevCOPD(di), di=2,..6 
And for di=1: 
N(ri,1,g,a) t=0 =prevsmok0(ri,g,a)N0(g,a) - Σdi>1 N(ri,di,g,a) t=0 
 
 
Find initial values for distributions. 
 
For the start year, the FEV1%pred-distributions within each COPD and smoking class 
are approximated by the distribution over all smoking classes. For the latter, the 
distributions defined by the coefficients given in Table C4 were normalized. 
 
distFEV(ri,di,c) t=0 = distFEV0(di,c) 
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As a result, for the start year, the mean FEV1%pred values within each smoking class 
are approximated by the mean values over all smoking classes, which are given as input 
variables: 
 
mFEV(ri,di) t=0 = mFEV0(di) 
 
Compute baseline incidence and baseline mortality rates 
In the model, COPD incidence and excess mortality rates per smoking and severity 
stage are calculated as a baseline rate multiplied by a relative risk. These baseline rates 
are to be calculated from the input data, which give overall incidence and mortality rates.  
The input incidence rates are divided by (1-prev), because data incidence rates apply to 
the general population and model incidence rates apply to the disease-free population 
only. Incidence cannot take place from the fraction of the population with COPD. They 
are moreover divided by ( Σri prevsmok(ri|1,g,a) RRsmokCOPD(ri,g,a)) to find the incidence rate 
for a non smoker.  
 
baseincCOPD(g,a) =incCOPD(g,a) / (1-prevCOPD0(g,a)) /( Σri prevsmok0(ri|1,g,a) RRsmokCOPD(ri,g,a)) 
 
COPD excess mortality is divided by (Σdi RRFEVtot^(10-.1mFEV0(di)) propprevCOPD(di)) to find 
the excess mortality rate for mild COPD. 
 
embaseCOPD(g,a) = excessmortCOPD(g,a) /(Σdi RRFEVtot^(10-.1mFEV0(di)) propprevCOPD(di)) 
 
Note that for di=1 (no COPD), mFEV0(di)=100, while for di=2, mFEV0(di) is very low 
(very severe COPD). For mFEV0(di)=100 it follows that: RRFEVtot^(10-.1 mFEV0(di))= 
RRFEVtot^0=1.  
 
Mortality from other causes is found as the remainder after subtraction of COPD excess 
mortality.  
 
mortoth(g,a) = morttot(g,a) – excessmortCOPD(g,a)prevCOPD0(g,a) 
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Simulation part 1: Apply the distribution of FEV1%pred on the population 
numbers in each severity stage and smoking class to find the fractions 
flowing to and from neighbour stages 
 
The fractions flowing from and to each severity stage as a result of the worsening of lung 
function over time (or the improvement of lung function for recent quitters) are called the 
COPD stage transition rates (transCOPD(j,ri,di)).  
These are calculated in the model for each year, using distribution characteristics for the 
distribution of FEV1%pred within each severity stage (see section 3.1) and lung function 
decrease/increase in that period, f(j,ri,di,g,a), that is defined as a function of lung function 
at the lower respectively upper boundary of each severity stage and was estimated 
based on the Lung Health Study data (see section 3.3). From the estimated function, the 
f(j,ri,di,g,a) are calculated as a function of age, gender, severity stage (i.e. lung function at 
the boundary of the severity stage) and smoking class. To find the COPD stage 
transition rates, the following steps are taken: 
 
First, the mean decrease and increase for each severity and smoking class is found as 
the weighted average over age and gender. Increases are only defined for ex smokers in 
the year of quitting. 
 
Mf(1,ri,di) = Σg,a (f(1,ri,di,g,a) N(ri,di,g,a)) / Σg,a N(ri,di,g,a), di=2,..6;ri=1,..3 
And 
Mf(2,3,di)= Σg,a (f(2,3,di,g,a) N(2,di,g,a) transsmok(1,2,g,a)) /Σg,a [N(3,di,g,a) + N(2,di,g,a) transsmok(1,2,g,a)] 
di=2,..6, with Mf(2,ri,di)=0; ri=1,2 
 
Second, new COPD stage transition fractions are calculated for each smoking and 
severity stage: 
 
 
for di=2,..6, with f1=Mf(j,ri,di). 
]
)di,2)]FEV1(ri,di,1)/disti,distFEV1(r(di)Abs[½FEVlength(1
)di,2)]i,distFEV1(r di,1)/i,distFEV1(r½f1Abs[(1th(di)[f1/FEVleng
di)ri,1,transCOPD(
+
+
=
]
)di,2)]FEV1(ri,di,1)/diststFEV1(ri,(di)Abs[di½FEVlength(1
)di,2)]i,distFEV1(r di,1)/ri,[distFEV1(½f1)-(di)(FEVlength½(1th(di)[f1/FEVleng
di)ri,2,transCOPD(
+
+
=
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The transition rates are used in part 2 of the simulation. The mean decreases are used 
in part 3 of the simulation. 
 
Simulation part 2: Find new population numbers, i.e. new COPD and 
smoking prevalence numbers 
 
 
The new smoking and COPD stage prevalence numbers are calculated. This uses the 
transCOPD values from part 1 of the simulations as well as the mFEV values. 
 
The population numbers in each smoking and severity stage change as a result of  
1. COPD related mortality  
2. Mortality from other causes  
3. Outflow to next smoking class (i.e. from non to current and from current to former 
smoker)  
4. Outflow to previous smoking class (i.e. from former to current smoker)  
5. Outflow to next, i.e. more severe COPD stage (equals 0 for very severe COPD) 
6. Outflow to previous, i.e. less severe COPD stage (equals 0 for mild COPD) 
7. COPD incidence 
8. Inflow from previous smoking class (i.e. new smokers and new former smokers)  
9. Inflow from next smoking class (i.e. restarting former smokers) 
10. Inflow from previous, i.e. less severe COPD stage (equals 0 for mild COPD) 
11. Inflow from next, i.e. more severe COPD stage (equals 0 for very severe COPD) 
 
This results in the following formulas for population numbers in the stages without and 
with COPD respectively: 
For di=1, 
N(ri,di,g,a+1)t+1 = N(ri,di,g,a)t  
(2) - RMoth(g,ri,a) mortoth(g,a) N(ri,di,g,a) t  
(3)  - transsmok(1,ri,g,a) N(ri,di,g,a) t  
(4)  - transsmok(2,ri,g,a) N(ri,di,g,a) t  
(7)   - baseincCOPD(g,a) RRsmokCOPD(ri,g,a) N(ri,di,g,a) t  
(8)  + transsmok(1,ri-1,g,a) N(ri-1,di,g,a) t  
(9)  + transsmok(2,ri+1,g,a) N(ri+1,di,g,a) t  
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For di>1,  
N(ri,di,g,a+1) t+1 = N(ri,di,g,a) t  
(1) - RRFEVtot^(10-.1mFEV(ri,di)) embaseCOPD(g,a) N(ri,di,g,a) t  
(2) - RMoth(g,ri,a) mortoth(g,a) N(ri,di,g,a) t  
(3) - transsmok(1,ri,g,a) N(ri,di,g,a) t  
(4) - transsmok(2,ri,g,a) N(ri,di,g,a) t  
(5) - transCOPD(1,ri,di) N(ri,di,g,a) t  
(6) - transCOPD(2,ri,di) N(ri,di,g,a) t  
(7) + baseincCOPD(g,a) RRsmokCOPD(ri,g,a) propincCOPD(di) N(ri,1,g,a) t  
(8) + transsmok(1,ri-1,g,a) N(ri-1,di,g,a) t  
(9) + transsmok(2,ri+1,g,a) N(ri+1,di,g,a) t  
(10) + transCOPD(1,ri,di+1) N(ri,di+1,g,a) t 
(11) + transCOPD(2,ri,di-1) N(ri,di-1,g,a) t 
 
These new population numbers are corrected for birth in the lowest age class to 
complete this part of the simulation. 
 
Simulation part 3: Calculate new distributions of FEV1%pred and new mean 
FEV1% pred values specific to smoking and severity stage  
 
The new distributions of the FEV1%pred within each COPD stage are calculated from 
the existing distributions, the mean decrease and increase for each severity and 
smoking class (Mf(j,ri,di)) found in part 1, as well as the population numbers per age, 
gender, smoking and severity stage.  
First, the normalized distributions are multiplied by the stage prevalence numbers to get 
absolute frequency numbers. These stage prevalence numbers are aggregations over 
gender and age for each smoking class and COPD stage. 
 
distFEVp(ri,di,c) := distFEV(ri,di,c) Σg,a N(ri,di,g,a), for di=2,..6 
 
Second, the new frequency numbers are calculated taking into account the inflow from 
and outflow to neighbor COPD severity stages over 1 year (the mean decreases and 
increases), as well as COPD incidence and mortality. These calculations use severity 
and smoking class specific decreases and increases (the Mf(j,ri,di)) and severity and 
smoking class specific coefficients (the distFEVp(ri,di,c)) to find severity and smoking 
class specific new coefficients for the frequency distribution. 
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The frequency numbers change as a result of  
1. the inflow from the previous, i.e. milder stage to decrease in lung function (based on 
Mf(1,ri,di+1))  
2. the outflow to the next, i.e. more severe stage due to decrease in lung function 
(based on Mf(1,ri,di)) 
3. the inflow from the next, i.e. more severe stage due to increase in lung function for 
current quitters (based on Mf(2,ri,di-1)),  
4. the outflow to the previous, i.e. milder stage due to increase in lung function for 
current quitters (based on Mf(2,ri,di)).  
5. Incidence from the COPD-free population into the severity stages  
6. COPD related mortality  
7. Mortality from other causes  
It must be remarked that the two flows 3 and 4 are in practice very small.  
 
Changes 1 to 4 result in new frequency distributions taking into account decrease or 
increase, but not taking into account incidence and mortality. The specific functional form 
is complex and is not presented here:  
distFEVp1(ri,di,c) t+1 = g (distFEVp(ri,di,c) t, di,Mf(j,ri,di),Mf(j,ri,di+1),Mf(j,ri,di-1)) ; ri=1,2,3; di=2,..6 
By assumption, for the stage of mild COPD no outflow is allowed to the COPD-free 
population due to increases in lung function for current quitters. These remain in mild 
COPD. 
 
Adding change 5, incidence is distributed over the severity stages di=2,..6, according to 
the input parameter propinc COPD(di) that gives the fractions of incidence into the severity 
stages. The distribution of incidence within each severity stage is given by 
distFEVinc(di,c). This is also an input parameter (see table C4, the values in the table 
were normalized to form the distFEVinc(di,c)). 
 
distFEVp2(ri,di)t+1=distFEVp1(ri,di) t+1 
+ distFEVinc(di) t*Σg,a [baseincCOPD(g,a)* RRsmokCOPD(ri,g,a)* N(ri,1,g,a) t*propincCOPD(di)]  
 
The new frequency distributions are corrected for mortality, taking into account that 
COPD excess mortality depends on lung function. That means, persons with lower 
FEV1% values have higher COPD-related mortality risks. This differential mortality within 
each COPD severity stage results in a change of both intercept and slope of the linear 
(frequency) distribution function. 
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Slopes are corrected as follows: 
 
distFEVp(ri,di,1) t+1 =  
distFEVp2(ri,di,1) t+1 ∗ [ ( 1 – { Σg,a (RMoth(ri,g,a) mortoth(g,a) N(ri,di,g,a) ) / Σg,a N(ri,di,g,a) } )  
        – (RRFEVtot^(10-.1mFEV(ri,di)) { Σg,a (embaseCOPD(g,a)N(ri,di,g,a) ) / Σg,a N(ri,di,g,a) }  / 
EFm(di) ) ] 
– distFEVp2(ri,di,2)t+1 ∗  [ RRFEVtot^(10-.1mFEV(ri,di))  
                            { Σg,a (embaseCOPD(g,a)N(ri,di,g,a) )/ Σg,a N(ri,di,g,a) }  (-0.1log(RRFEVtot )) / 
EFm(di) ] 
 
Intercepts are corrected as follows : 
 
distFEVp(ri,di,2) t+1 =  
distFEVp2(ri,di,2) t+1 ∗ [ ( 1 –{ Σg,a (RMoth(ri,g,a) mortoth(g,a) N(ri,di,g,a) ) / Σg,a N(ri,di,g,a) } )  
            – RRFEVtot^(10-.1mFEV(ri,di)) { Σg,a (embaseCOPD(g,a)N(ri,di,g,a) )/ Σg,a N(ri,di,g,a) }  / 
EFm(di) ] 
 
Here EFm(di) denotes an approximation of the expectation of the increased lung function 
dependent mortality risk over the severity stage di: 
 
  dy0) 2), di,,distFEV(ri   y* 1) di,i,(distFEV(r max y))(RR 0.10log-(1  EFm(di)
di)FEVlength(
0
FEV
tot∫ +∗=
for di=2,..6 
 
The term max(.,0) is used to guarantee non-negative frequency numbers. 
Finally these new frequency distributions are normalized again and new mean 
FEV1%pred values are calculated. 
 
  ∫ +=
di)FEVlength(
0
dy 0) 2), di,i,distFEVp(r   y* 1) di,ri,(distFEVp( max / di)i,distFEVp(r  di),distFEV(ri  
  ∫ ++=
di)FEVlength(
0
dy 0) 2), di,,distFEV(ri   y* 1) di,i,(distFEV(r max*y)FEVbord(di  di)mFEV(ri,  
for di=2,..6 
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The mean FEV values as well as the new normalized distribution functions are used in 
the next simulation step. 
 
Simulation part 4: Compute results for other smoking related diseases and 
save outcomes. 
 
The remainder of the model follows the structure of the CZM and describes the 
incidence, prevalence and mortality from other smoking related diseases in relation to 
the number of never, current and ex-smokers, and to mortality and birth.  
 
Save results  
 
Finally the results are saved before a new simulation step is started.  
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Appendix D: Tables of chapter 5 results: projections for the 
base-case scenario 
 
Table D1: Age-and gender specific prevalence rates for 2000 and 2025 (number per 
1000) 
 Men Women 
Age class 2000 2025 2000 2025 
45-49 year 15.9 12 13.9 10 
50-54 year 25.0 18 19.7 20 
55-59 year 40.5 31 25.9 33 
60-64 year 64.3 53 33.8 48 
65-69 year 104.4 85 48.8 67 
70-74 year 144.5 125 63.0 85 
75-79 year 167.4 164 65.4 92 
80-84 year 178.5 198 59.5 92 
85+ 175.8 191 61.6 110 
Total 24.0 33 14.7 27 
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Table D2: Age- and gender specific prevalence rates per severity stage in 2000 (per 
1000) 
 Men Women 
 Mild Moderate Severe Very 
severe 
Mild Moderate Severe Very 
severe 
45-49 
year 
4.2 8.8 2.5 0.4 3.7 7.7 2.2 0.4 
50-54 
year 
6.7 13.9 3.9 0.7 5.3 10.9 3.1 0.5 
55-59 
year 
10.8 22.4 6.3 1.1 6.9 14.4 4.0 0.7 
60-64 
year 
17.1 35.6 10.0 1.7 9.0 18.7 5.2 0.9 
65-69 
year 
27.7 57.8 16.2 2.7 13.0 27.1 7.6 1.3 
70-74 
year 
38.4 80.0 22.4 3.8 16.7 34.9 9.8 1.6 
75-79 
year 
44.4 92.7 25.9 4.3 17.4 36.2 10.1 1.7 
80-84 
year 
47.4 98.8 27.6 4.6 15.8 33.0 9.2 1.6 
85+ 46.7 97.3 27.2 4.6 16.3 34.1 9.5 1.6 
Total 6.4 13.3 3.7 0.6 3.9 8.1 2.3 0.4 
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Figure D1a: Proportional distribution of severity stages over time for men 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure D1b: Proportional distribution of severity stages over time for women 
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Table D3: Total costs in million Euros per age and gender class for the years 2000 and 
2025  
 Men Women 
Age class 2000 2025 2000 2025 
45-49 year 6.36 4.06 6.81 4.48 
50-54 year 9.88  7.25 10.3 11.2 
55-59 year 11.9 12.8 10.1 19.1 
60-64 year 16.6 22.3 11.4 27.5 
65-69 year 25.0 33.6 16.4 36.5 
70-74 year 29.8 45.0 18.5 39.6 
75-79 year 30.5 57.0 18.7 41.7 
80-84 year 16.7 35.8 11.6 27.0 
85+ 13.7 30.2 15.6 40.0 
Total 160 248 119  247  
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Appendix E: Tables of chapter 6 results: sensitivity analysis for 
the base-case scenario 
 
Table E1: Sensitivity analyses on the proportional distribution over smoking classes for 
all sensitivity analyses for the year 2025 
 Men   Women   
 Never 
smoker 
Smoker Ex-
smoker 
Never 
smoker 
Smoker Ex-
smoker
Base-case 5.8 44.2 50.0 10.8 49.9 39.2 
       
1. Distribution of 
prevalence over severity 
stages differs by age 
class 
5.8 43.9 50.3 10.9 49.6 39.5 
2. Severity distribution of 
incidence as prevalence 
5.8 44.3 49.9 10.8 50.0 39.1 
3. Severity distribution of 
incidence: 60% in mild, 
40% in moderate 
5.7 44.1 50.2 10.8 49.8 39.4 
4, Decline in FEV1% 
pred as base-case –10% 
5.8 44.2 50.0 10.8 49.9 39.2 
5. Decline in FEV1% 
pred as base-case  
+10% 
5.8 44.2 50.1 10.8 49.9 39.3 
6. No increase in FEV1% 
pred after smoking 
cessation 
5.8 44.3 49.9 10.9 50.0 39.1 
7. Never smoker has 
decline smoker 
5.7 44.2 50.1 10.7 50.0 39.3 
8. More than exponential 
association between 
lung function and 
mortality  
5.8 44.2 50.0 10.8 49.9 39.2 
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Table E2: Sensitivity analyses on the percentage of COPD patients dying in 2025 
 Men Women
Base-case 8.7 7.2 
   
1. Distribution of prevalence over severity stages differs by age class 8.6 7.0 
2. Severity distribution of incidence as prevalence 9.2 7.7 
3. Severity distribution of incidence: 60% in mild, 40% in moderate 8.2 6.7 
4, Decline in FEV1% pred as base-case –10% 8.7 7.1 
5. Decline in FEV1% pred as base-case  +10% 8.8 7.2 
6. No increase in FEV1% pred after smoking cessation 8.7 7.2 
7. Never smoker has decline smoker 8.7 7.2 
8. More than exponential association between lung function and 
mortality  
8.8 7.2 
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Table E3: Sensitivity analyses on the percentage of COPD patients dying per severity 
stage in 2025  
  Mild Moderate Severe Very 
severe 
Base-case Men 7.4 8.6 11.1 14.2 
 Women 5.9 7.1 9.3 12.0 
      
1. Distribution of prevalence over 
severity stages differs by age class 
Men 
Women 
7.3 
5.8 
8.4 
6.9 
11.0 
9.2 
14.3 
12.1 
      
2. Severity distribution of incidence 
as prevalence 
Men 
Women 
7.5 
5.9 
8.6 
7.1 
10.8 
9.1 
13.7 
11.7 
      
3. Severity distribution of incidence: 
60% in mild, 40% in moderate 
Men 
Women 
7.4 
5.9 
8.6 
7.0 
11.9 
9.7 
14.7 
12.3 
      
4. Decline in FEV1% pred as base-
case –10% 
Men 
Women 
7.4 
5.9 
8.6 
7.1 
11.1 
9.3 
14.1 
12.0 
      
5. Decline in FEV1% pred as base-
case  +10% 
Men 
Women 
7.4 
5.9 
8.5 
7.1 
11.1 
9.3 
14.2 
12.0 
      
6. No increase in FEV1% pred after 
smoking cessation 
Men 
Women 
7.4 
5.9 
8.5 
7.1 
11.2 
9.3 
14.4 
12.1 
      
7. Never smoker has decline smoker Men 7.4 8.6 11.1 14.2 
 Women 5.9 7.1 9.3 12.0 
      
8. More than exponential association 
between lung function and mortality  
Men 
Women 
7.5 
6.0 
8.5 
7.0 
11.1 
9.3 
15.1 
12.9 
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Table E4: Sensitivity analyses on the total costs due to COPD per severity stage in 
million Euros in 2025 
  Mild Moderate Severe Very 
severe 
Base-case Men 26 75 70 76 
 Women 25 73 70 79 
      
1. Distribution of prevalence over 
severity stages differs by age class 
Men 
Women 
27 
26 
77 
74 
70 
69 
76 
78 
      
2. Severity distribution of incidence 
as prevalence 
Men 
Women 
18 
17 
69 
66 
109 
107 
152 
152 
      
3. Severity distribution of incidence: 
60% in mild, 40% in moderate 
Men 
Women 
39 
37 
72 
70 
23 
25 
39 
43 
      
4. Decline in FEV1% pred as base-
case –10% 
Men 
Women 
27 
26 
77 
74 
68 
67 
62 
64 
      
5. Decline in FEV1% pred as base-
case  +10% 
Men 
Women 
26 
24 
74 
71 
73 
73 
92 
95 
      
6. No increase in FEV1% pred after 
smoking cessation 
Men 
Women 
25 
24 
75 
72 
73 
72 
85 
86 
      
7. Never smoker has decline smoker Men 26 75 70 78 
 Women 25 72 71 82 
      
8. More than exponential association 
between lung function and mortality  
Men 
Women 
26 
25 
75 
73 
71 
71 
74 
77 
 
 
 
